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Abstract 
 
Aims 
To determine whether there is variability in the care and management of patients 
with seizures and epilepsy, when comparing those aged 60 and over to those under 
60.  
 
Review whether there has been change in referral rates and pattern of referral for 
older patients with seizures presenting to emergency departments (ED).  
 
Assess yield of CT head imaging carried out in patients with known epilepsy.  
 
Methods 
Patients aged 60 and over were compared to those under 60 recruited to National 
Audit of Seizure Management in Hospitals 2 (NASH2). NASH2 assessed care 
antecedent to the presenting seizure, care at hospital, in the emergency 
department, medical wards as well as future plans for the patient. Data collection 
was carried out between June to September 2013. Statistical analysis was carried 
out using GraphPad Prism. 
 
Two retrospective case note audits were also carried out, using the same clinical 
questions as NASH2 reviewing the care of all patients aged 60 and over, attending 
University Hospital Aintree (UHA) and Royal Liverpool University Hospital (RLH) ED, 
from December 2014 to June 2015, presenting with a seizure. CT scans, of patients 
with known epilepsy were reviewed to assess yield of imaging.  
 
 
Results 
1256 patients, aged 60 and over, were recruited in NASH2 and included for analysis. 
110 patients attending University Hospital Aintree and 60 patients attending Royal 
Liverpool Hospital were identified. 
 
Results from NASH2 showed that 80% of patients aged 60 and over and 55% of 
those under 60 presenting with a likely first seizure were admitted to hospital 
(p<0.001).  
 
CT head imaging in patients with epilepsy in NASH 2 was carried out in 35% of 
patients aged 60 and over compared to 17% of those under 60 (p<0.001).   
 
Review of CT imaging in patients with epilepsy at UHA showed that 97% had no 
new abnormalities. The findings at RLH were similar with 92% of patients with 
epilepsy having no new abnormalities on CT imaging. 
 
34% of patients aged 60 and over with a likely first seizure in NASH2 were referred 
to a specialist on discharge, compared to 68% of patients under 60 (p<0.001).   
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27% of patients with a likely first seizure attending UHA and 43% attending RLH 
were referred to a neurologist or epilepsy specialist on discharge. Referral to other 
specialties was made in 14% of those with a likely first seizure presenting to UHA 
and 18% of those presenting to RLH. 
 
Conclusions 
Older patients presenting with seizures are more likely to be admitted to hospital 
and have imaging. They are less likely to be referred to specialist services on 
discharge. There appears to be significant disparity in referral rates when 
comparing those aged 60 and over to the under 60s, with those aged 60 and over 
less likely to be referred.  
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Chapter 1.  Introduction 
 
The proportion of the world’s population aged 60 and over will nearly double from 
12% to 22% from 2015 to 2050. By 2050 the number of people aged 60 and over 
will outnumber children younger than 5. (1) The incidence of epilepsy varies with 
age and peaks in children and older people. Epilepsy is the third most common 
neurological condition, following dementia and stroke in this group. (2, 3)  
 
The ageing population present a unique set of challenges to clinicians, both in terms 
of diagnosis, treatment and long-term management. Guidance on diagnosis and 
management of epilepsy and seizures in older people remains limited, with minimal 
guidance offered by the National Institute for Health and Care Excellence (NICE). 
Whilst the Scottish Intercollegiate Guidelines Network (SIGN) on management of 
older people with epilepsy provides more guidance this only highlights certain 
aspects of management. (4, 5) 
 
 
1.1 Epidemiology 
 
Chronic neurological disorders, including epilepsy, account for a significant 
proportion of the world’s disease burden. The Global Burden of Disease Study was a 
comprehensive analysis of the burden of 291 diseases and injuries, and 67 risk 
factors, in 187 countries and 21 world regions comparing the years 1990, 2005 and 
2010. The burden of disease was measured by disability-adjusted life years (DALYs). 
Mental, neurological and substance use disorders were the fifth cause of DALYs. 
Neurological disorders accounted for 3% of DALYs, a quarter of these were due to 
epilepsy. (6-8)  
 
Among neurological diseases, epilepsy accounts for the highest age-standardised 
DALY rates both in men and in women, followed by migraine and Alzheimer’s 
disease (AD). Epilepsy accounted for 0.7% of total DALYs, with a 16% increase of 
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DALYs observed in both men and in women when comparing 1990 and 2010. This 
increase is largely due to changes in population growth and ageing. (6-8) 
 
 
1.1.2 Prevalence of epilepsy 
The estimated median worldwide incidence of epilepsy is 50.4 per 100,000 
population per year. (9) Significant differences can be found when comparing 
developing to developed countries (incidence, 81.7 vs. 45.0). The differences can in 
part be explained by the level of income in the country. Similarly the higher 
incidence of traumatic brain injury and infections may contribute to the increased 
incidence of epilepsy in some areas. (3)  
 
Older people are more likely to develop seizures and epilepsy than their younger 
counterparts. The annual incidence of epilepsy rises from 85.9 per 100 000 people 
in those aged over 65 to more than 135 per 100 000 people in those over 80. (2, 3, 
10, 11)  
 
The increase in the incidence of epilepsy with age is largely explained by the 
increased incidence of common clinical conditions in older people, such as 
neurodegenerative disorders and stroke. (12) Acute symptomatic seizures are also 
more common in older people, adding to the burden of disease. (13) 
 
 
1.1.3  Comorbidities and mortality in epilepsy 
A comorbid condition is one that occurs during the course of a pre-existing disease. 
(14) Comorbidity increases in the elderly with 30.4% of adults aged 45 to 64 years 
reporting at least two chronic conditions, increasing to 64.9% of adults aged 65 to 
84 years and more than 80% for those above 85 years old. (15) Almost all deaths in 
people with epilepsy are related to other comorbidities of epilepsy, such as cancer, 
cardiovascular, or cerebrovascular disease. (16, 17) 
 
10 
 
Population-based studies report an increased risk of premature mortality among 
people with epilepsy compared to the general population. Pooled mortality was 
threefold, relative risk 3.33 (95% confidence interval 2.83–3.92) of observed deaths 
in epilepsy compared to that expected in the general population. (17, 18) 
 
For individuals with symptomatic epilepsy, around three-quarters of deaths within 
one year of epilepsy onset, are directly related to the underlying cause of epilepsy, 
for individuals with symptomatic epilepsy, rather than seizure-related causes. (19) 
 
Data from the National General Practice Study of Epilepsy, a community-based UK 
study with almost 25 years of follow-up, has shown that people with epilepsy are 
more likely than the general population to die of malignant neoplasms, ischaemic 
heart disease, cerebrovascular disease, and pneumonia, after controlling for the 
effects of age, sex, and calendar year. (20) 
 
Epilepsy itself carries a significant risk of premature death and sudden unexplained 
death in epilepsy (SUDEP). (21, 22) A pooled analysis of population-based studies 
showed that SUDEP has an estimated overall crude annual incidence rate of 0.81 
cases per 100,000 population, or 1.16 cases per 1,000 patients with epilepsy. 
Although the rate of SUDEP declines in the sixth decade, SUDEP still contributes to 
mortality in this group. (23) 
 
The frequency of status epilepticus and incidence per 100,000 individuals is highest 
in the first year of life and in individuals aged 60 and over. 30% of older patients 
presenting with seizures do so in status epilepticus, with associated mortality rates 
of 38%. (24) 
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1.2 Causes of epilepsy in older people 
 
1.2.1 Cerebrovascular disease 
People with epilepsy have higher rates of heart disease, stroke, as well as 
hypertension, diabetes mellitus and hyperlipidaemia. (25-29) The occurrence of 
epilepsy in older people should lead to investigation for underlying cerebrovascular 
disease.  
 
A retrospective review of stroke admissions to hospital found that epilepsy was 
more common in the stroke group compared to controls, suggesting that seizures 
were a possible predictor of future stroke. (30)  
 
A further study looking at the risk of stroke in adults aged 60 and over following a 
seizure confirmed a substantial risk of stroke at any point when comparing those 
who developed seizures to controls (hazard ratio [HR] = 2.89). (31)  
 
When assessing time to stroke following initial diagnosis of epilepsy, another study 
found that onset of stroke between six months and one year after the first 
diagnosis, occurred in a significantly higher proportion of cases with epilepsy 
(16.2%) than controls (10.9%). The median time to stroke was significantly shorter 
in cases with epilepsy (2.7 years) when compared to controls (3.2 years). (32) 
 
Acute seizures following stroke have been defined as occurring between 2-4 weeks 
later. (33) Risk factors for post stroke epilepsy include haemorrhagic stroke, as well 
as stroke severity and location. Local factors such as ischaemia, oedema, 
cytotoxicity, and altered neurotransmitter activity, are thought to be implicated in 
seizure occurrence. (33-36)  
 
Some studies also suggest that the risk of epilepsy is higher in patients with late 
onset seizures following stroke. (30, 37, 38) A prospective multicentre study 
showed that 8.9% of patients had seizures following stroke, of these 10.6% had a 
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haemorrhagic stroke and 8.6% ischaemic stroke. Late onset of first seizure was 
shown to be an independent risk factor for epilepsy after ischaemic but not after 
haemorrhagic stroke. (39) 
 
Focal neurological symptoms can lead to a diagnosis of transient ischaemic attacks 
(TIA) rather than seizures, and vice versa. The duration of symptoms is helpful at 
reaching a diagnosis, a shorter duration typically less than five minutes is more 
suggestive of seizures than TIAs. Patients who have been diagnosed as having TIAs 
who describe concurrent loss of awareness should be re-assessed for seizures. (40) 
 
 
1.2.2 Neurodegenerative conditions 
In Europe the prevalence of dementia is estimated to be approximately 6–8% after 
65 years of age and may rise to 20–30% in subjects older than 85. (41, 42) Although 
Alzheimer’s disease (AD) is the most common form of dementia, other causes 
include, vascular disease, frontal lobe dementia and Lewy body disease. (43) 
 
The aetiology of seizures in individuals with AD remains unclear and several 
mechanisms have been suggested, including deposition of β-amyloid in the brain, 
leading to cognitive impairment and seizures. (44) Seizures have also been 
observed in patients with vascular dementia, where cerebrovascular disease is felt 
to play a part.  (45) 
 
Age is a common factor for both epilepsy and dementia.  Several studies have 
noted a significantly higher incidence of seizures and epilepsy in patients with 
dementia.  Patients with AD are up to ten times more likely to develop epilepsy 
than those without. (46-50) 
 
In a prospective study of 453 patients with mild AD, 2% had an unprovoked seizure 
by 5 years of follow-up, this is 8 times higher when compared with the general 
population. (51, 52)  
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The diagnosis of AD has consequences with regards to quality of life, morbidity and 
it can also lead to increase in mortality in individuals with both conditions. (53)  
 
Other independent risk factors for seizure include degree of cognitive impairment 
and history of antipsychotic use. (54) Some drugs used for treatment of AD have 
been associated with an increased risk of seizure by lowering seizure threshold, 
including typical neuroleptics and the antidepressant bupropion. (55)  
 
Acetylcholinesterase inhibitors are the mainstay of current symptomatic treatments 
for patients with AD. A randomised, double-blind, placebo-controlled study of 
donepezil, an acetylcholinesterase inhibitor, in patients with epilepsy did not reveal 
an increased frequency of seizures. (56) Memantine, a non-competitive NMDA 
receptor antagonist, has been reported to have both anti-convulsant and pro-
convulsant effects in rats. (57) 
 
Anti-epileptic drugs (AEDs) particularly if used in combination can lead to significant 
cognitive side effects, making this a particular consideration when choosing AEDs in 
individuals with pre-existing cognitive impairment. (58) Lamotrigine appears to 
have a more favourable cognitive profile. (59) Conversely topiramate can cause 
effects on attention, verbal function and language (60) There is paucity of data on 
cognitive side effects of AEDs. However general principles on the use in this group 
should include slow titration and avoidance of multiple AEDs where possible.  
 
 
1.2.3 Trauma 
Traumatic brain injury (TBI), has a higher occurrence and poorer prognosis in older 
people. (61) Up to 20% of cases of epilepsy in older people can be attributed to TBI. 
(62) A study of young adults and children found a strong correlation between the 
severity of TBI and the risk of subsequent unprovoked seizure. The risk remained 
elevated for more than 10 years, compared to people without TBI. (63)  
 
14 
 
Risk factors for subsequent epilepsy include, subdural haematoma, contusion, skull 
fracture, loss of consciousness, amnesia for more than a day, as well as those aged 
65 or older. (64) 
 
 
1.2.4 Acute symptomatic seizures 
The incidence of acute symptomatic seizures in patients older than 60 is 
approximately 100 per 100,000 population and increases with each decade of 
advancing age. (13, 65, 66) Acute symptomatic seizures represent approximately 
40% of all cases of non-febrile seizures in developed countries, and more than half 
in some geographic areas, where cysticercosis is endemic. (67, 68)  
 
Traumatic brain injury, cerebrovascular disease, drug withdrawal, infection, and 
metabolic insults represent the commonest causes for acute symptomatic seizures. 
The peak incidence of seizures related to alcohol withdrawal occurs in late adult 
life. (69, 70)  
 
Medications that lower the seizure threshold are an important cause of acute 
seizures. Drugs such as antipsychotics, antidepressants, theophylline, levodopa, 
thiazide diuretics and antibiotics have been reported to induce seizures.  All 
barbiturates and benzodiazepines present a risk of withdrawal seizures. (71-74) 
 
Acute symptomatic seizures arising from metabolic conditions are common in 
patients older than 60. Several conditions can precipitate seizures. Hypoglycemia 
associated with insulin use and non-ketotic hyperglycemia are often reported 
causes of seizures in diabetic patients. (75, 76) Uraemia, hypocalcaemia and 
hyponatremia  can also promote seizures. (77) Similarly central nervous system and 
systemic infections, such as meningitis, pneumonia, and urinary sepsis, can provoke 
seizures. (78) 
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Short-term mortality is fairly high after an acute symptomatic seizure and a first 
episode of status epilepticus. (66) 30% of acute seizures in older people presented 
as status epilepticus (SE), which is twice the incidence of SE in the general 
population. (79) 
 
 
1.2.5 Tumours 
Between 10% and 30% of seizures are associated with tumours, brain metastases, 
meningiomas, and gliomas. (65) Seizures are more commonly seen in low-grade 
tumours rather than high-grade tumours and in primary brain tumours rather than 
secondary. (80) Older people with brain tumours are less likely than younger 
patients to present with seizures, however age is a risk factor for increased 
mortality in people who do develop seizures. (81) 
 
 
1.3 Diagnosis 
Studies carried out in various settings have reported epilepsy misdiagnosis rates of 
between 4.6% and 30%. (82) Specialists have lower misdiagnosis rates than non-
specialists, with a misdiagnosis rate of 5.6% for neurologists compared with 18.9% 
for non-specialists. (83) The need for review by a specialist for diagnosis and 
management of epilepsy is recommended by both SIGN and NICE, with the latter 
suggesting referral to a tertiary neurosciences unit if diagnostic doubt persists. (4, 
5)  
 
The diagnosis of epilepsy can be even more challenging in older patients, making 
this group prone to both underdiagnosis and overdiagnosis.  The true extent of 
misdiagnosis remains unclear and consequently the exact prevalence of epilepsy in 
older people remains difficult to quantify. (12) 
 
In the Veterans Affairs Cooperative Study of epilepsy in older people, epilepsy was 
not considered in 26% of initial medical evaluations of older patients who were 
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eventually diagnosed with epilepsy.  Alternative diagnoses considered were altered 
mental status (41.8%), blackouts (29.3%), syncope (16.8%), confusion (37.5%), 
memory disturbance (17.2%), dementia (6.9%) and dizziness (10.3%). (84) 
 
The lack of typical clinical signs in older people who have had a seizure, may lead to 
delayed diagnosis and treatment. Several factors contribute to the difficulties in 
diagnosis and recognition of seizures in this group, including lack of awareness and 
understanding of the symptoms, by both patients and carers, leading to under 
reporting of events to clinicians. Variability in clinical presentation of seizures and 
comorbid medical disorders also make diagnosis difficult. Lack of knowledge about 
epilepsy and lack of training in diagnosis and management can also reduce 
clinicians’ ability to reach a diagnosis. (85) 
 
The symptoms of epilepsy in older people are often attributed to other comorbid 
conditions. 13% of patients admitted with a diagnosis of stroke, to an acute stroke 
unit had an incorrect diagnosis.  39% of these patients had  unrecognised seizures 
rather than stroke. (86) Post ictal focal motor deficits may last for several hours 
which can mistakenly lead to a diagnosis of ischaemic stroke. (87) 
 
Overdiagnosis of transient ischaemic attacks (TIAs) has been reported in older 
people, particularly in patients who have a previous diagnosis of TIAs.  For older 
patients with a previous diagnosis of TIA or stroke time to diagnosis of epilepsy was 
1.7 years. (88) 
 
Overdiagnosis of syncope has also been noted and felt to be primarily due to high 
prevalence of false positives in tilt table testing, carotid sinus massage and 
electrocardiographic monitoring. (89) 
 
Medical literature focuses more on clinical features that are useful in establishing or 
excluding a diagnosis of syncope rather than on making a diagnosis of seizures or 
epilepsy. Furthermore, there is little information specifically relating to the clinical 
features of seizures in older people. A scoring system based on common clinical 
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features has been proposed to distinguish syncope from seizures with 94% 
sensitivity and specificity. (90) 
 
Seizures in older people can be atypical with non-specific symptoms and signs. 
Auras are less commonly reported. Up to one-third of patients experience focal 
seizures with loss of awareness. Older people may have more prolonged periods of 
post ictal confusion and automatisms may not be as prevalent. Tongue biting and 
urinary incontinence may also be absent. (87) 
 
Seizures can also be a presenting feature of autoimmune encephalitis (AE). The 
diagnostic criteria for AE include progressive working memory deficits, altered 
mental status or psychiatric symptoms. These should be accompanied by at least 
one of the following; new focal clinical findings, seizures not explained by a 
previous known seizure disorder, cerebrospinal fluid pleocytosis, and MRI features 
suggestive of AE. (91) 
 
Whilst auto-antibody testing is useful to allow prognostication and potentially 
identify underlying aetiology, it is important to treat suspected individuals with AE 
early with immunotherapy, and not wait for antibody results, particularly given that 
these patients are often immunotherapy-responsive.  
(91, 92) 
 
 
1.3.1 Confusional states 
Prolonged confusion might be a feature of the ictal or post-ictal phases in older 
patients with epilepsy. Transient confusion should always prompt consideration of 
focal seizures. In patients with pre-existing dementia confusional states can be 
particularly challenging to diagnose. (93)   
 
Non-convulsive status epilepticus (NCSE) should be considered in patients 
presenting with altered mental status. Older patients are at particular risk of 
misdiagnosis given the lack of motor signs and broad range of presentations. (94) 
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Similarly it is important to consider this diagnosis in patients with a low Glasgow 
coma scale (GCS) and therefore an early electroencephalogram (EEG) should be 
considered in these patients. (79, 95) 
 
Several conditions with episodic neurological symptoms or loss of consciousness 
can be mistaken with epilepsy. Transient global amnesia (TGA) is characterised by 
abrupt-onset anterograde amnesia, with a duration of 1-12 hours during which time 
there is repetitive questioning without impairment in consciousness. (96) TGA is 
usually an isolated event with recurrence being uncommon. (97) TGA should be 
distinguished from focal seizures with loss of awareness or from transient epileptic 
amnesia, which typically lasts less than an hour and can reoccur. (98) 
 
The prevalence of epilepsy in the migraine population, ranges from 1% to 17% and 
the frequency of migraine in epileptic populations, ranges from 8.4% to 20%. (99)  
 
Studies have found that whilst neocortical cellular excitability is apparent in both, in 
migraine the hyperexcitability is believed to transition to cortical spreading 
depression, rather than to the hypersynchronous activity that characterizes 
epilepsy. Some forms of epilepsy and migraine are known to be channelopathies 
and genetic mutations can lead to epilepsy, migraine or both. (100) 
 
 Whilst epilepsy and migraine can be easily differentiated, difficulties can arise 
when distinguishing migrainous visual aural from occipital lobe seizures, and 
therefore a detailed description of the visual phenomena is particularly important. 
(101) 
 
 
1.3.2 Sleep disorders 
Rapid eye movement sleep behaviour disorder (REMSBD) is a type of parasomnia 
that usually presents in older men. During rapid eye movement (REM) sleep these 
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patients are reported to thrash limbs, may walk about, or engage in more complex 
activity. (102) 
 
REMSBD can be difficult to distinguish from nocturnal frontal lobe seizures, which 
arise from sleep, and can present with violent movements, automatisms and 
vocalisations. However, REMSBD tends to occur in the second half of sleep, 
comparatively nocturnal frontal lobe seizures usually present in childhood, and can 
be of shorter duration. (103, 104)  
 
The Frontal Lobe Epilepsies and Parasomnias (FLEP) scale is a series of questions 
aimed at reflecting the diagnostic features of nocturnal frontal lobe epilepsy (NFLE) 
and parasomnias. A total score of 1 or greater indicating a diagnosis of epilepsy and 
a score of zero or less indicating parasomnias. The FLEP score was shown to have 
good sensitivity of 1.0 (95% confidence interval [CI], 0.85-1.00) and specificity of 
0.90 (95% CI, 0.73-0.97) when used to diagnose nocturnal frontal lobe epilepsy 
when compared to clinical diagnosis.  (105) 
 
Periodic leg movements and restless leg syndrome are other parasomnias that are 
common in older people, and these need to be considered in the differential 
diagnosis of nocturnal motor events. A sleep study with concurrent video-EEG 
monitoring might be required to distinguish epileptic seizures from sleep disorders 
in older people. (106) 
 
 
1.3.3 Diagnostic evaluation 
The interictal EEG can be of limited diagnostic value in older people due to high 
rates of non-specific abnormalities. A study of older people who underwent video-
EEG monitoring, found that 26% of those with non-epileptic events had interictal 
epileptiform discharges as did 75% of those with epilepsy. (107) 
 
Video-EEG can be useful if patients have frequent atypical events, and can in these 
situations help differentiate between epileptic and non-epileptic events. (108)  
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Patients with definite epilepsy or recurrent events of uncertain aetiology should 
undergo brain imaging to detect any underlying structural abnormalities.  MRI is the 
preferred imaging modality. In older people, brain imaging may show evidence of 
previous cerebral infarction, or small vessel ischaemic change. However, the 
presence of these abnormalities does not necessarily infer that the event was an 
epileptic seizure. (109) 
 
 
1.4 Pharmacological treatment 
Age related changes in the body may lead to adjustments in dosage and drug 
selection in older people. (110) Changes in the pharmacodynamics and 
pharmacokinetics of AEDs in this population also depend on the effects of co-
existing medication and comorbidities. (111) 
 
Several physiological changes occur with ageing that can affect medication 
pharmacokinetics and may therefore lead to an increased risk of adverse effects. 
The absorption of drugs might be reduced in older people. A decrease in lean body 
mass, combined with a progressive reduction in hepatic and creatinine clearance 
have been observed with increasing age, resulting in higher serum AED 
concentrations than in younger adults.  Therefore, lower doses of AEDs may need 
to be used in patients with moderate to severe renal failure. (112-114)  
 
The binding of drugs to serum proteins can reduce with age due to decreased 
serum albumin levels. This results in an increased protein free fraction for drugs 
that are highly protein bound, such as phenytoin and sodium valproate. (115) 
 
Ageing leads to a progressive decline in counter-regulatory homoeostatic 
mechanisms in the brain, making it a particularly sensitive pharmacological target. 
Therefore the rate of adverse events tends to be higher in older people, supporting 
the principle of starting AEDs at a low dose and titrating these slowly in this group. 
(116) 
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Co-existing comorbidities are very common in older patients and are an important 
consideration in the management of epilepsy in this population. Older individuals 
are often on multiple medications that can interfere with AEDs, or vice versa. Many 
older patients are receiving antihypertensives, antiarrhythmic agents, 
anticoagulants, diuretics, lipid lowering medication, and psychoactive medication at 
the time of diagnosis. The main interactions of concern are effects of drugs on 
protein binding and hepatic enzymes. Enzyme inducing antiepileptic medications 
can induce the metabolism of other concomitant medications. (112) 
 
Phenytoin and carbamazepine can lower the serum concentration of simvastatin 
and reduce the efficacy of warfarin. (117)  Phenytoin can also compete with 
coumadin for protein binding and can displace this drug, leading to increased  
concentration of free coumadin in the serum. (118) 
 
Fluoxteine, an enzyme inhibitor can increase carbamazepine levels. (119) Herbal 
supplements taken by older people can add to the potential for interactions. Some 
herbal remedies affect cytochrome P450 enzyme systems. Other herbal remedies 
such as star anise and ginkgo biloba can increase the risk of seizures due to their 
intrinsic proconvulsant properties. (120, 121) 
 
Various mechanisms have been suggested for the reduction of bone density in 
patients with epilepsy, one of these is enzyme-inducing AEDs accelerating vitamin D 
metabolism resulting in lowered levels of 25 hydroxy-vitamin D [25 (OH) D] and 1 
alpha, 25 (OH) 2D. (122) Another proposed mechanism is that non enzyme-inducing 
AEDs may lead to hypocalcemia, stimulating parathyroid hormone release, with the 
aim of restoring serum calcium levels at the expense of bone calcium. (122) 
 
Patients with epilepsy have a 2-6 times greater risk of bone fractures compared 
with the general population, in particular of the vertebral bodies and femoral neck. 
There are several potential explanations for this, including fractures caused by 
seizure-related injuries or associated with the osteopenic effect of reduced physical 
activity. (123-125)  
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The duration of AED treatment is associated with the rate of drug-induced bone 
loss. (126) Reduced bone mineral content is observed in 20–65% of patients with 
long-term use of AEDs. (127) 
 
Enzyme-inducing AEDs are associated with an increased fracture risk. (128, 129) 
Phenytoin, an enzyme inducer has the greatest potential to affect bone and mineral 
metabolism. (130, 131) The data on carbamazepine, which is also an enzyme 
inducer, and sodium valproate, an enzyme inhibitor, are somewhat conflicting, but 
in some studies both drugs have been associated with osteopenia. (132, 133) 
 
Drugs which inhibit carbonic anhydrase, such as topiramate and zonisamide, can 
have an unfavourable influence on bone metabolism by causing metabolic acidosis. 
(134) Data from animal studies show that levetiracetam reduces bone strength 
without altering bone mass. (135) There are no data on direct association between 
lamotrigine and fractures. (136) 
 
A study assessing the effects of oxcarbazepine and levetiracetam monotherapy on 
the levels of calcium, ionized calcium, and vitamin D in epileptic patients, found 
that patients taking oxcarbazepine had lower calcium, ionized calcium, and vitamin 
D compared to controls. Patients taking levetiracetam however did not differ 
significantly from controls in terms of calcium, ionized calcium, and vitamin D 
levels. (137) 
 
Healthy older people with epilepsy can be managed in a similar way to younger 
adults. Treatment decisions should be individualised. (138) Older individuals who 
are frail or have multiple comorbidities need to be treated with an AED that has a 
favourable side effect and tolerability profile. Those with multiple medical problems 
should be started on AEDs that do not interact with existing medication. Special 
consideration should also be given to nursing home residents who are receiving 
AEDs as they are often on five or six other routine medications. (139)  
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1.4.1 Clinical trials 
Clinical trials assessing the management of epilepsy in the general population are 
also likely to be of relevance in older people. Older individuals are exposed to an 
increasing number of risk factors for seizures and epilepsy often due to pre-existing 
comorbidities such as stroke and AD. Focal epilepsy is therefore more likely in this 
group rather than genetic generalised epilepsy. (140) 
 
Older studies into management of focal epilepsy concluded that carbamazepine 
was the most effective AED, making carbamazepine first line treatment for focal 
epilepsy. (141, 142) Subsequent trials comparing carbamazepine to lamotrigine 
found that the latter is better tolerated, with comparable rates of seizure freedom 
between the two. A substantial body of evidence supports the use of lamotrigine as 
first line therapy for focal onset epilepsy. (143-146) 
 
The veterans’ administration (VA) cooperative double blind, multicentre, 
randomized trial, compared carbamazepine, phenobarbital, phenytoin and 
primidone in 622 adult patients with partial epilepsy. Patients were followed up for 
2 years or until the drug failed to control seizures or caused unacceptable adverse 
effects. Overall treatment success was highest with carbamazepine or phenytoin, 
intermediate with phenobarbital, and lowest with primidone (p<0.002). 
Carbamazepine and phenytoin were felt to be the AEDs of choice for single-drug 
therapy of adults with partial or generalized tonic-clonic seizures or with both. (141) 
 
A second VA cooperative trial with a similar design compared carbamazepine and 
sodium valproate and found carbamazepine to be more effective for focal seizures. 
The two drugs were equally effective for secondary generalised tonic–clonic 
seizures. Carbamazepine had fewer long-term adverse effects than sodium 
valproate. (142)  
 
Lamotrigine and carbamazepine were compared in a multicentre, double blind trial 
involving 150 older patients with newly diagnosed epilepsy. The two drugs were 
similar regarding efficacy measures, but the dropout rate due to adverse events 
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was much lower for patients treated with lamotrigine than those treated with 
carbamazepine. Furthermore, side effects of somnolence were less commonly 
observed with lamotrigine. (143) 
 
A further VA cooperative trial compared lamotrigine and gabapentin to 
carbamazepine in a multi-centre, randomised, double blind, double dummy, 
parallel study of 593 older individuals with newly diagnosed seizures. The target 
doses were lamotrigine 150 mg per day, carbamazepine 600 mg per day and 
gabapentin 1,500 mg per day. The primary outcome measure was retention in the 
trial for 12 months. (146) 
 
Early terminations occurred more often in the carbamazepine group than in the 
other two groups, mostly owing to adverse events (P = 0.0002). No significant 
differences were noted between groups with regards to seizure freedom at 12 
months. The study concluded that lamotrigine or gabapentin should be considered 
as initial therapy for older patients with newly diagnosed seizures. (146)  
 
These findings are not supported by further studies. Lamotrigine was better than 
both carbamazepine and gabapentin in a large, unblinded, randomized, controlled 
trial in focal epilepsy. This trial also showed that in terms of time to treatment 
failure, lamotrigine was superior to topiramate and had a non-significant advantage 
over oxcarbazepine. (144) 
 
The studies described above all used immediate release carbamazepine which is 
not as well tolerated as the sustained release preparation. Therefore, the sustained 
release formulation might be a better comparator for trials in this population.  
 
An international multicentre, randomized, double-blind, controlled trial of 
lamotrigine and sustained release carbamazepine in older individuals did not find 
significant differences in efficacy between these two drugs. However better 
tolerability with lamotrigine was observed. (145) 
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A randomised, open label controlled, parallel group, multicentre trial was 
conducted to test the superiority of levetiracetam over lamotrigine. The primary 
endpoint was the rate of seizure-free patients in the first 6 weeks. 409 patients 
were included with newly diagnosed focal or generalised epilepsy. There were no 
significant differences with regard to efficacy and tolerability of levetiracetam and 
lamotrigine in newly diagnosed focal and generalised epilepsy despite more rapid 
titration in the levetiracetam arm. (147) 
 
Carbamazepine and phenytoin are strong enzyme inducers with potential for 
adverse interactions. The nonlinear kinetics of phenytoin might be particularly 
problematic in older  individuals given that the phenytoin dose curve is much 
steeper in older than in younger adults. (148) Considerable variability in serum 
phenytoin concentrations has also been noted in older nursing home residents. 
(149) 
 
The binding of phenytoin to serum proteins may decrease with age. If only total 
AED serum levels are considered in dose adjustments, continued titration can 
potentially lead to toxic effects at what may appear therapeutic total AED levels. 
This makes the dosage of phenytoin difficult to manage in older people and yet this 
drug has been shown to be widely prescribed for seizures in the nursing home 
setting. (150) 
 
Carbamazepine is a potent inducer of cytochrome P450 enzymes and shows 
numerous interactions with other drugs. Carbamazepine can also lead to 
hyponatremia, which older patients are already susceptible to developing, thereby 
increasing the risk of this occurring. Carbamazepine and phenytoin are both 
associated with increased serum levels of cholesterol and c-reactive protein, which 
are markers of vascular risk. The levels of these markers decrease when patients 
are switched to lamotrigine or levetiracetam. (151) 
 
Sodium valproate, whilst not an enzyme inducer, is highly protein bound. The 
protein free portion can increase in low protein states and in the presence of other 
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highly protein bound medications. A study evaluating the influence of ageing on the 
pharmacokinetics of sodium valproate at steady-state, and the susceptibility of 
sodium valproate metabolism to enzyme induction by other AEDs, showed that 
sodium valproate clearance in older patients receiving enzyme inducing AEDs was 
lower than in controls. The measurements of clearance were based on total serum 
sodium valproate concentrations. The difference was felt to be secondary to ageing 
as well as the fact that mean sodium valproate dosage was lower in these patients 
than in controls. (114) 
 
Chronic sodium valproate treatment has also been associated with parkinsonism in 
older patients. (152) Sodium valproate can be considered with caution in older 
individuals if generalised epilepsy is suspected.  
 
Oxcarbazepine has been studied extensively as first line monotherapy for focal 
epilepsy, however experience with this drug in older people is limited.  
Oxcarbazepine has been associated with hyponatremia in older individuals, 
particularly if administered with diuretics. Furthermore, hyponatremia was more 
common and more pronounced with oxcarbazepine than with carbamazepine. 
(153, 154)  Oxcarbazepine could be a treatment option in healthy older people but 
should be considered with caution in older people who have multiple medical 
conditions. 
  
A randomised comparison of low dose topiramate (50 mg/day) versus high dose 
(200 mg/day) in older people with focal onset seizures favoured the low-dose 
regimen. Efficacy was similar with the two dosages when topiramate was used as 
monotherapy, however the 200 mg dosage was more effective than 50 mg as 
adjunctive therapy, supporting results from a previous study. (155, 156) 
 
Topiramate has an unfavourable cognitive profile in comparison with lamotrigine, 
and therefore should be used cautiously in older patients who may have co-existing 
cognitive impairment. Other common adverse events of topiramate include 
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dizziness, headache and drowsiness. (157) Given the side effect profile, topiramate 
requires slow titration in older individuals. 
 
Levetiracetam has been shown to have equal efficacy and tolerability to controlled 
release carbamazepine. (158) A randomised controlled trial assessing the 
effectiveness of controlled-released carbamazepine to levetiracetam and 
lamotrigine in older patients with newly diagnosed focal epilepsy, showed that 
retention with levetiracetam was higher compared to controlled-release 
carbamazepine due to better tolerability. Retention of lamotrigine was 
intermediate and close to levetiracetam. (159) 
 
A small retrospective study suggested that levetiracetam monotherapy can be  
effective in older patients with newly diagnosed epilepsy, who were not on any 
AEDs, as well as in older patients with epilepsy.  (160) 
 
A Cochrane review of monotherapy in epilepsy concluded that levetiracetam may 
be a suitable alternative to carbamazepine and lamotrigine as first-line treatment 
for individuals with focal onset seizures.(161)  
 
Levetiracetam clearance declines significantly with ageing, and older patients may 
require between 30% and 50% lower doses, compared to their younger 
counterparts to achieve a given levetiracetam plasma concentration. (162) 
 
Zonisamide is a newer anti-epileptic drug licensed for use in focal epilepsy.  The 
pharmacokinetic profile of zonisamide, lack of induction or inhibition of hepatic 
enzymes and mild interactions with other drugs, makes it favourable for the 
management of epilepsy in older people. (163, 164) 
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1.4.2 Anti-epileptic drug choice 
Older people who have more than one unprovoked seizure should be started on 
anti-epileptic medication. Treatment of a first unprovoked seizure reduces the risk 
of a subsequent seizure. It does not however, affect the proportion of patients in 
long-term remission. Antiepileptic drugs are associated with adverse events, and 
there is no evidence that they reduce mortality. Therefore, the decision to start 
antiepileptic drug treatment following a first unprovoked seizure should be 
individualized and based on patient preference, clinical, cultural and social factors. 
(165) 
 
There is no indication for the long-term prophylactic use of antiepileptic drugs in 
older patients who have been diagnosed with brain tumours or severe traumatic 
brain injury. (166, 167) 
 
Older patients are more likely to develop focal epilepsy, however non-epileptic 
attacks can also present in this age group and should be considered in the 
differential diagnosis. (168, 169) The majority of older patients with epilepsy 
become seizure free on AED monotherapy at moderate dosage. (170) Focal epilepsy 
is more likely to be refractory to treatment and there is evidence that sodium 
valproate is not the best first AED to achieve seizure freedom. (144, 146, 171)  
 
As outlined sodium valproate has also been implicated in reduction of bone density 
and increased risk of fractures in this group. (129, 172, 173) The continued use of 
sodium valproate for older patients with newly diagnosed epilepsy reflects 
outdated practice and is likely to be a consequence of management of these 
patients in primary care or by non-specialist services.  
 
To date only five randomised controlled trials of AED monotherapy in older people 
with newly diagnosed epilepsy have been carried out. (143, 145, 146, 159, 174) 
Four of the trials have shown comparable efficacy, in terms of time to first seizure, 
or seizure freedom between carbamazepine and lamotrigine. (143, 145, 146, 174) 
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Retention rates were higher for lamotrigine than carbamazepine in these trials, 
mainly due to better tolerability with lamotrigine. (159) 
 
There are no recognised differences in efficacy among all the available drugs for the 
treatment of newly diagnosed epilepsy, therefore choice will depend on the side-
effect profile and tolerability. (158, 175) Typically if the first drug is not tolerated 
then a second drug should be tried, ideally with a different mechanism of action 
compared to the first one. (176) Toxicity in older patients may present at a lower 
dose.  
 
Older people are more likely than their younger counterparts to develop 
idiosyncratic skin reactions with AEDs, particularly with phenobarbital, phenytoin, 
carbamazepine, lamotrigine, oxcarbazepine, and zonisamide. (177) 
 
Surgical treatment for refractory epilepsy can be considered in older people 
however the complication rates are higher. (178) 
 
 
1.5 Psychosocial factors 
The consequences of epilepsy are as important to older people as they are their 
younger cohorts. Older adults are more likely to experience isolation. It is estimated 
that 17% of older adults are in contact with their family, friends, and neighbours 
less than once a week, and half of all people aged 75 and over live alone. (179) 
 
Older adults diagnosed with epilepsy post-retirement age were more likely than 
those diagnosed pre-retirement to be both mildly anxious and mildly or moderately 
depressed, though the differences were not statistically significant. (180) 
 
These findings were supported by a further study which showed that mean health 
questionnaire depression scores were higher for patients with epilepsy than 
controls with no diagnosis, indicating more depressive symptoms in patients with 
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epilepsy (4.2 vs. 0.8; p=0.006). Mean patient health anxiety scores were also higher 
for older patients with epilepsy than controls (3.7 vs. 0.0; p=0.001). (181) 
 
Infrequent seizures can impair quality of life suggesting that in older adults the 
apprehension induced by the possibility of a further seizure may be enough to 
reduce health-related quality of life. A greater perception of stigma and more 
frequent seizures was also strongly related to poor quality of life and reduced 
psychosocial function.  (182)  
 
Furthermore, isolation from loss of driving, restriction in employment, social 
embarrassment from seizures and safety are major concerns expressed by older 
patients who have seizures. Medication side effects also appear to be of concern. 
(183) 
 
 
1.6 Aims 
One of the main aims of this project was to assess differences in care provided to 
patients with seizures and epilepsy, comparing those aged 60 and over to those 
under 60.   
 
High rates of CT head imaging, in patients with epilepsy, were noted in NASH2 
however it was beyond the scope of NASH2 to explore this further. As part of the 
two audits, older patients with epilepsy who had CT head imaging had their reports 
reviewed aiming to assess the yield of this investigation.  
 
Referral to specialist services in NASH2, was kept as broad as possible, however 
NASH2 was not set up to review referral patterns in older people. The two local 
audits aimed to ascertain whether there had been any change to referral rate of 
older patients with seizures presenting to ED, and if referred which speciality this 
was to.  
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Chapter 2.  Methods 
 
2.1  National Audit of Seizure Management in Hospital 2  
This study presents data from the National Audit of Seizure management in 
Hospitals (NASH2). (184)  NASH2 collated data on patients presenting with seizures 
to EDs, and assessed the care they received prior to admission, management of the 
acute event and follow-up arrangements. 
 
2.1.1 Site selection and recruitment 
NASH2 was coordinated from the University of Liverpool and overseen by a 
multidisciplinary steering committee consisting of representatives from neurology, 
emergency medicine, primary care, a patient charity, Information Systems and 
statistics.  
 
Letters to the Chief Executives and Heads of Clinical Audit, and emails to 
participants from NASH2, were sent in February 2013 to all Trusts/Health Boards in 
England, Scotland, Wales and Northern Ireland which had sites with EDs, 
representing 165 UK trusts. 132 trusts participated, with some Trusts having more 
than one site take part, resulting in data collection from 154 sites.   
 
Each site was asked to identify up to 30 consecutive adult patients who presented 
at the ED from 1st January 2013 with an episode thought to have been a seizure 
(the following International Classification of Diseases 10 (ICD10)  codes were used 
as an indication of potential seizure: G40.0, G40.1, G40.2, G40.3, G40.4, G40.5, 
G40.6, G40.7, G40.8, G40.9, G41.0. G41.1, G41.2, G41.8, G41.9, R56.1 and R56.8), 
and where the seizure was the primary reason for their admission/attendance.  
 
Patients presenting to ED, who were either admitted or discharged were selected, 
providing an index point and opportunity to identify first seizure, new epilepsy 
cases as well as established cases with uncontrolled seizures.  
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2.1.2 Data collection 
The proforma captured the clinical care pathway for individual patients. The 
questions were based on the NICE and SIGN guidelines (4, 185) augmented by the 
practical experience of the steering committee. The clinical proforma was divided 
into sections covering the care antecedent to the presenting seizure, the care at 
hospital (in the ED and on medical wards) and the future plans for the patient. 
Recognising the constraints on data collectors, a limited range of items was 
collected.  
 
The two proformas were piloted, with duplicate collections from 60 patients across 
10 sites, and the questions amended and refined to reduce ambiguities and 
inconsistencies. (Appendix 1)  
 
Data was entered anonymously into a bespoke web-based audit system. Online 
help was available for the majority of questions. Data entry took place from June to 
September 2013, when follow up information should have been available. If an 
individual attended more than once, each attendance was treated as a separate 
event. 
 
Initial diagnosis and management were carried out by medical staff in ED, with 
onward referral and admission to hospital as clinically indicated.  The following 
investigations were documented: AED levels, computed tomography (CT) head, 
electrocardiogram (ECG), electroencephalogram (EEG), glucose levels and magnetic 
resonance imaging (MRI) head.    
 
In keeping with other published data, patients aged 60 and over were selected from 
the NASH2 data set. In order to assess whether there was a difference in patient 
management according to age, management of patients aged 60 and over was 
compared to those under 60. 
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Results are shown as the percentage for all patients. Statistical analysis was carried 
out using Chi-square test, with 95% confidence interval. Analysis was carried out 
with GraphPad Prism.  
 
 
2.1.3 Terminology 
Review by senior – evidence of review by senior doctor in ED, deemed to be 
speciality or consultant grade.  
Eyewitnesses account – either collateral history from person attending with patient 
in ED or separate contact for collateral history. 
Documentation of alcohol intake – DoH guidance recommends alcohol use should 
be documented in all, and especially where it is a known provoking factor for the 
event. 
Care plan – This is a NICE quality statement, patients with epilepsy should have a 
written care plan in place. (4) What this constituted was open to interpretation by 
local auditors. 
Recording of data – recording temperature, and recording GCS, should be routine 
practice. 
Neurological examination –a full neurological examination including plantar reflex 
and fundi examination. 
Specialist review – was kept as broad as possible and included, general practitioner 
with specialist interest in epilepsy (GPSI), learning disability psychiatrist, 
neurologist, epilepsy nurse specialist, alcohol and drug liaison service or 
neurosurgeon. 
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2.2 Audits - University Hospital Aintree and Royal Liverpool 
University Hospital 
 
Two retrospective case note audits were carried out reviewing the care of all 
patients aged 60 and over, attending University Hospital Aintree (UHA) and Royal 
Liverpool University Hospital (RLH) ED, from December 2014 to June 2015, with an 
episode thought to have been a seizure and where this was the primary reason for 
admission or attendance. If an individual attended more than once, each 
attendance was treated as a separate episode.  
 
Patients fulfilling the criteria for analysis were identified by the local audit 
departments. The same clinical questions used in NASH2 were also used for the 
purposes of these audits. Additional information on previous medical conditions 
was also collected. (Appendix 2) 
 
The outcome measures used in NASH2 have been used for these audits, aiming to 
assess care prior, during, and after ED attendance.  
 
Patients with epilepsy who had CT imaging had their reports reviewed. These were 
then subdivided into patients whose CT imaging showed no new abnormalities or 
acute changes, and those where a new abnormality or acute change was noted. 
With regards to abnormal findings these were deemed to be findings which would 
alter acute patient management, such as stroke or intracerebral haemorrhage. 
 
With regards to onward referral to specialist services these audits aimed to collect 
data of referral to any speciality, not just neurology, for older patients attending ED 
with seizure.  In line with NASH2, results are shown as percentages for all patients. 
 
 
 
35 
 
Chapter 3. Results 
 
3.1 Results - National Audit of Seizure Management in Hospitals 2 
3.1.1 NASH 2 - Statistical analysis 
For the purposes of analysis patients in NASH2 were divided into the following 
categories: 
1. Those recorded as having known epilepsy prior to attendance. 60 and over 
(n=640; 51%) under 60 (n=2115; 65%). 
2. Those known to have had previous seizures or blackouts, but not a diagnosis 
of epilepsy. 60 and over (n=209; 17%) under 60 (n=556, 17%). 
3. Those with likely first seizure, with no previous seizures, blackouts or 
diagnosis of epilepsy. 60 and over (n= 405; 32%) under 60 (n=606, 18%).  
 
 
3.1.2 NASH 2 - Patient characteristics 
Of the total 4531 patients, 1256 (28%) were aged 60 years and over and included 
for analysis (median age 74 years, IQR 66-82, 54% men). 87% (1088/1256) of the 
clinical information was entered by doctors, 8% (104/1256) by nurses, 5% (64/1256) 
by audit staff or other healthcare professionals.  2 patients could not be classified 
with regards to diagnosis and were excluded from analysis. 
 
 
3.1.3 NASH 2 - Treatment prior to admission 
In the known epilepsy group 44% (281/640) had presented to ED with a seizure in 
the preceding 12 months as did 41% (85/209) of patients with previous seizure or 
blackout.   
 
In patients with known epilepsy 86% (552/640) were documented as taking AED 
treatment. 59% (377/640) were on monotherapy, 27% (175/640) were on two or 
more AEDs (i.e. polytherapy). (Table 1, Figure 1)  
36 
 
Sodium valproate was the most commonly used AED both as monotherapy 28% 
(181/640) and polytherapy 42% (267/640). 9% (56/640) of patients with epilepsy 
were on carbamazepine monotherapy, 8% (50/640) phenytoin monotherapy, 9% 
(40/640) lamotrigine monotherapy and 9% (39/640) on levetiracetam 
monotherapy. 
 
In those aged 60 and over with epilepsy 28% percent (179/640) had evidence of 
contact with an epilepsy specialist recorded in the year preceding their attendance, 
compared to 40% (842/2115) of patients under 60. Only 30% (189/640) of patients 
aged 60 and over with epilepsy had a written care plan in place.  
 
Figure 1. Number of anti-epileptic drugs by diagnosis 
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Table 1. Anti-epileptic drug treatment and review prior to presentation – Patients 
aged 60 and over and under 60 
 Patients with 
diagnosis of 
epilepsy 
Patients with 
previous 
seizure/blackout 
Patients with likely 
first seizure  
60 and 
over 
% 
(n=640) 
Under 60 
% 
(n=2115) 
60 and 
over 
% 
(n=209) 
Under 60 
% 
(n=556) 
60 and 
over% 
(n=405) 
Under 60 
% 
(n=606) 
No AEDs 14% 
(88) 
19% 
(410) 
71% 
(148) 
84% 
(466) 
95% 
(383) 
95% 
(577) 
Monotherapy 59% 
(377) 
45% 
(950) 
26% (55) 14% (78) 5% (19) 4% (26) 
Two or more 
AEDs 
27% 
(175) 
36% 
(755) 
3% (6) 2% (12) 1% (3) 0% (3) 
Specialist 
review in the 
past 12 
months 
28% 
(179) 
40% 
(842) 
25% (52) 32% 
(176) 
7% (27) 2% (43) 
AEDs – Anti-epileptic drugs. 
 
 
3.1.4 NASH 2 - Assessment on arrival 
The majority of patients had their GCS and temperature checked on arrival to ED. 
The figures were similar for those over and under 60. 57% (364/640) of patients 
with epilepsy had a neurological observation chart in place within 4 hours of arrival. 
46% (97/209) of patients with previous seizure or blackout had a neurological 
observation chart started. In those presenting with a likely first seizure aged 60 and 
over, only 2 of 405 patients had a neurological observation chart started, compared 
to 50% (303/606) of patients under 60 presenting with a likely first seizure. (Table 2, 
Figure 2) 
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Figure 2. GCS and neurological observation chart in patients aged 60 and over 
compared to under 60 
 
 
In patients presenting with a likely first seizure 43% (175/405) had plantar reflexes 
checked. Fundoscopy was only carried out in 15% (60/405).   
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Senior review or discussion with a senior in ED was carried out in 57% (229/405) of 
patients presenting with a likely first seizure and in 59% (377/640) of patients with 
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Table 2. Assessment on arrival to emergency department – Patients aged 60 and over and under 60 
 Patients with diagnosis of epilepsy Patients with previous 
seizure/blackout 
Patients with likely first seizure 
60 and over 
% (n=640) 
Under 60 
% (n=2115) 
60 and over 
% (n=209) 
Under 60 
% (n=556) 
60 and over 
% (n=405) 
Under 60 
% (n=606) 
GCS Score 88% (561) 89% (1892) 90% (189) 92% (514) 91% (369) 90% (544) 
Neuro obs chart 57% (364) 49% (1026) 46% (97) 48% (266) 0% (2) 50% (303) 
Temperature 92% (587) 92% (1953) 94% (198) 94% (520) 90% (367) 92% (557) 
Fundoscopy  12% (74) 13% (272) 17% (35) 15% (84) 15% (60) 21% (127) 
Plantar reflex 33% (213) 29% (615) 40% (85) 34% (190) 43% (175) 41% (247) 
Eyewitness account 73% (464) 64% (1361) 81% (170) 65% (360) 80% (323) 72% (436) 
Review by senior ED 
doctor 
59% (377) 57% (1206) 61% 
(127) 
58% (325) 57% (229) 60% (363) 
Documented alcohol 
intake 
27% (174) 40% (851) 42% (87) 59% (326) 31% (126) 59% (359) 
Admission 74% (474) 50% (1065) 62% (131) 47% (263) 80% (326) 55% (331) 
ED – accident and emergency department; Neuro obs – Neurological observation chart. 
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Rates of admission were higher in patients aged 60 and over compared to those 
under 60. (Table 2, Figure 3)  
 
Figure 3. Admission to hospital and senior review in ED in patients aged 60 and over 
compared to under 60 
 
 
In patients aged 60 and over presenting with a likely first seizure 80% (326/405) 
were admitted to hospital, compared to 55% (331/606) of those under 60 
(p<0.001). 74% (474/640) of patients aged 60 and over with epilepsy presenting 
with a seizure were admitted to hospital, compared to 50% (1065/2115) of those 
under 60 (p<0.001).   
 
Documentation of alcohol intake was lower for patients aged 60 and over 
presenting with a likely first seizure and was carried out in 31% (126/405), 
compared to 59% (359/606) of those under 60. 
 
 
3.1.5 NASH2 - Inpatient management  
ECG, a NICE guideline-recommended investigation, was documented in 91% 
(370/405) of patients aged 60 and over presenting with a likely first seizure and in 
83% (534/640) of those aged 60 and over with known epilepsy. (17) (Table 3) 
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Advice or review by neurology during admission was low across the board when 
compared between patients aged 60 and those under 60. 
 
CT head imaging was the primary imaging modality, with only 3-4% of patients aged 
60 and over having MRI. 71% (290/405) of patients aged 60 and over with a likely 
first seizure had a CT scan on admission, compared to 43% (259/606) of those 
under 60 (p<0.001)  
 
In those aged 60 and over with epilepsy 35% (226/640) had a CT scan during 
admission compared to only 17% (369/2115) of those under 60 ( p<0.001).  (Table 
3, Figure 4) 
  
Figure 4. CT head in patients aged 60 and over compared to under 60 
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Table 3. Assessment and review during admission – Patients aged 60 and over and under 60 
 Patients with diagnosis of epilepsy Patients with previous 
seizure/blackout 
Patients with likely first seizure 
60 and over 
% (n=640) 
Under 60 
% (n=2115) 
60 and over 
% (n=209) 
Under 60 
% (n=556) 
60 and over 
% (n=405) 
Under 60 
% (n=606) 
CT 35% (226) 17% (369) 44% (91) 28% (153) 71% (290) 43% (259) 
CT GCS 3-8  44% (31/70) 46% (49/107) 65% (13/20) 25% (3/12) 87% (45/52) 81% (13/16) 
CT GCS 9-12 45% (43/95) 27% (43/162) 38% (8/21) 48% (14/29) 73% (29/40) 63% (19/30) 
CT GCS 13-15 32% (128/396) 15% (249/1621) 43% (63/148) 27% (128/472) 69% (192/277) 42% (207/496) 
MRI 3% (17) 2% (41) 4% (8) 3% (17) 8% (33) 7% (43) 
ECG 83% (534) 64% (1359) 86% (180) 77% (427) 91% (370) 84% (508) 
Glucose 86% (550) 80% (1696) 86% (180) 82% (456) 87% (352) 86% (523) 
Advice or review 
by neurology 
22% (143) 21% (435) 20% (42) 18% (100) 21% (87) 17% (101) 
CT – Computed tomography
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32% (128/396) of patients aged 60 and over with known epilepsy, and GCS of 13-15 
on admission, went on to have a CT. This figure is much higher than for those under 
60 where only 15% (249/1621) with a GCS of 13-15 went on to have a CT.  (Figure 5)  
 
The number of CTs carried out did not differ between age groups, bar those aged 
over 90 where the rate of CTs carried out was significantly lower. (Table 4, Figure 6) 
 
Figure 5. CT head stratified by GCS score in patients aged 60 and over compared to 
under 60 
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Figure 6. CT head stratified by age group and diagnosis 
 
 
Table 4. CT head by age group and diagnosis 
Age Patients with 
diagnosis of epilepsy 
 % (n=226) 
Patient with previous 
seizure/blackout 
% (n=91) 
Patients with likely 
first seizure 
% (n=290) 
60-69 33% (75) 31% (28) 28% (81) 
70-79 32% (72) 33% (30) 33% (95) 
80-89 31% (70) 26% (24) 33% (86) 
>90 4% (9) 10% (9) 10% (28) 
 
 
3.1.6 NASH2 - Care following admission 
Patients who died during admission were excluded from analysis of follow-up 
arrangements  
1. Those recorded as having known epilepsy prior to attendance. 60 and over 
(n=622), under 60 (n=2114). 
2. Those known to have had previous seizures or blackouts, but not a diagnosis 
of epilepsy. 60 and over (n=208), under 60 (n=554). 
3. Those with likely first seizure, with no previous seizures, blackouts or 
diagnosis of epilepsy. 60 and over (n= 390), under 60 (n=603). 
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Seizure was quoted as the cause of death in only one patient with known epilepsy 
(1/18) and in one presenting with likely first seizure (1/15).  
 
Only 22% (90/390) of patients aged 60 and over presenting with a likely first seizure 
were given advice on what to do should they go on to have further seizures, 
compared to 29% (175/603) of those aged under 60. (Table 5)  
 
 
Table 5. Seizure management and specialist referral - Patients aged 60 and over and 
under 60 
 Patients with 
diagnosis of 
epilepsy 
 
Patients with 
previous 
seizures/blackouts  
Patients with likely 
first seizure  
 
60 and 
over 
% 
(n=622) 
Under 
60  
% 
(n=2114) 
60 and 
over  
% 
(n=208) 
Under 
60 
% 
(n=554) 
 
60 and 
over 
% 
(n=390) 
Under 
60 
% 
(n=603) 
Seizure 
management  
27% 
(172) 
28% 
(592) 
25% (53) 27% 
(150) 
22% (90) 29% 
(175) 
Epilepsy 
specialist 
referral as 
outpatient 
33% 
(206) 
46% 
(982) 
42% (87) 65% 
(360) 
34% 
(131) 
68% 
(411) 
 
 
34% (131/390) of patients aged 60 and over, presenting with a likely first seizure 
were referred by ED, or asked to be referred by their GP, for an epilepsy outpatient 
review compared to 68% (411/603) of those under 60. (Figure 7)  
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Figure 7. Seizure management and specialist referral in patients aged 60 and over 
and under 60 
 
 
There was a downward trend in referral rate by age group. 42% (105/252) of 60-69 
year olds with epilepsy were referred on discharge compared to 24% (35/157) of 
those 80-89. 52% (57/110) of 60-69 year olds presenting with a likely first seizure 
were referred compared to 25% (29/116) of patients aged 80-89. (Table 6, Figure 8)  
 
In patients with epilepsy aged 60 and over 33% (206/622) were referred to a 
specialist on discharge compared to 46% (982/2114) of those aged 60 and under 
(p<0.001). 34% (131/390) of patients aged 60 and over and 68% (411/603) aged 
under 60 with a likely first seizure were referred to a specialist on discharge 
(p<0.001).  
 
53% (94/176) of patients aged 60 and over with epilepsy, who had contact with 
neurology services in the preceding 12 months, were referred to epilepsy services 
on discharge, compared to 25% (112/445) of patients with epilepsy who had not 
been seen.   
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Figure 8. Referral to specialist services by age group 
  
 
Table 6. Seizure management and specialist referral by age group 
 Patients with 
diagnosis of epilepsy  
% (n=622) 
Patient with previous 
seizures/blackouts  
% (n=208) 
Patients with likely 
first seizure  
% (n=390) 
Seizure management by age group 
60-69 28% (71/252) 21% (16/76) 20% (22/110) 
70-79 29% (55/189) 25% (17/67) 23% (30/130) 
80-89 26% (41/157) 30% (14/47) 25% (29/116) 
> 90 22% (5/23) 35% (6/17) 30% (9/30) 
Specialist referral by age group 
60-69 42% (105/252)  59% (45/76)  52% (57/110)  
70-79 33% (62/189)  44% (30/68)  32% (42/130)  
80-89 24% (37/157)  21% (10/47)  25% (29/116)  
>90 13% (3/23)  12% (2/17)  10% (3/30)  
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3.2 Results - Audit University Hospital Aintree 
 
121 patients were identified. Of these 11 had been coded incorrectly and had not 
had seizures. Analysis was carried out on the remaining 110 patients (median age 
72, IQR 66-80, 45% male).  
For the purposes of analysis patients were divided into the following three 
categories: 
1. Those recorded as having known epilepsy, prior to attendance (n=58, 53%) 
2. Those known to have had previous seizures or blackouts, but not a diagnosis 
of epilepsy (n=12, 11%) 
3. Those with likely first seizures, no previous seizures or blackouts or 
diagnosis of epilepsy (n=40, 36%)  
 
 
3.2.1 UHA - Treatment prior to admission 
In patients with known epilepsy 66% (38/58) had presented to ED with a seizure in 
the preceding 12 months, as did 67% (8/12) of patients with a previous seizure or 
blackout. None of the patients presenting with a likely first seizure had attended ED 
in the preceding 12 months.  
 
Amongst those with known epilepsy 38% (22/58) had a history of stroke. 13% 
(5/40) of patients presenting with a likely first seizure had previously had a stroke. 
19% (11/58) of patients with epilepsy had a diagnosis of dementia compared to 
28% (11/40) of patients presenting with a likely new seizure.  
 
Two or more comorbidities were found in 38% (15/40) of patients presenting with a 
likely first seizure. In patients with known epilepsy 50% (29/58) had one 
comorbidity and 33% (19/58) had two. (Table 7, Figure 9) 
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Figure 9. Number of comorbidities by diagnosis 
 
 
Table 7. Number of comorbidities by diagnosis 
Number of 
comorbidities 
Patients with 
diagnosis of 
epilepsy   
% (n= 58) 
Patients with 
previous 
seizure/blackout  
% (n= 12) 
Patients with 
likely first seizure  
% (n= 40) 
0 9% (5) 17% (2) 8% (3) 
1 50% (29) 42% (5) 33% (13) 
2 33% (19) 8% (1) 23% (9) 
>2 9% (5) 33% (4) 38% (15) 
 
 
Amongst patients with known epilepsy 97% (56/58) were on AED treatment. 66% 
(38/58) were on monotherapy, 31% (18/58) were on two or more AEDs or 
polytherapy. Sodium valproate was the most commonly used AED, 45% (26/58) 
polytherapy, 40% (23/58) monotherapy. Of those with known epilepsy 9% (5/58) 
were on carbamazepine monotherapy and 9% (5/58) on levetiracetam 
monotherapy. (Table 8, Figure 10) 
 
Of those with known epilepsy 36% (21/58) had been reviewed by an epilepsy 
specialist or neurologist in the preceding year. None of the patients with known 
epilepsy had a care plan in place.  
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Table 8. Anti-epileptic drug treatment and review prior to presentation 
 Patients with 
diagnosis of 
epilepsy   
% (n= 58) 
Patients with 
previous 
seizure/blackout  
% (n= 12) 
Patients with likely 
first seizure  
% (n= 40) 
No AEDs 3% (2) 92% (11) 93% (37) 
Monotherapy 66% (38) 8% (1) 8% (3) 
Two or more 
AEDs 
31% (18) 0% (0) 0% (0) 
Specialist 
review previous 
12 months 
36% (21) 17% (2) 8% (3) 
AED, anti-epileptic drug. 
 
 
Figure 10. Number of anti-epileptic drugs by diagnosis 
 
 
 
3.2.2 UHA - Assessment on arrival 
GCS was checked on arrival in 95% (104/110) of all patients. All patients had their 
temperature, checked on arrival. 28% (16/58) of patients with known epilepsy had 
a neurological examination, as well as 20% (8/40) of patients presenting with a 
likely first seizure. None of the patients had examination of the fundi. 
 
An eyewitness account was sought in 83% (33/40) of patients presenting with a 
likely first seizure and 88% (51/58) of patients with known epilepsy.  
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Senior review or discussion with a senior in ED within 4 hours of admission was 
carried out in 40% (16/40) of patients presenting with a likely first seizure. 22% 
(13/58) of patients with known epilepsy and 8% (1/12) of patients with previous 
blackouts were reviewed or discussed. (Figure 11) 
 
 
Figure 11. Admission to hospital and senior review in emergency department 
 
 
Only 5% (3/58) of patients with epilepsy were asked regarding alcohol intake. 30% 
(12/40) of patients presenting with a likely first seizure were asked regarding 
alcohol consumption as were 50% (6/12) of those with previous seizures or 
blackouts. 
 
Admission to hospital was carried out in 71% (41/58) of patients with known 
epilepsy. 88% (35/40) of those with a likely first seizure were also admitted as were 
67% (8/12) patients with previous seizures or blackouts. (Table 9) 
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Table 9. Assessments on arrival to emergency department 
 Patients with 
diagnosis of 
epilepsy  
% (n=58) 
Patients with 
previous 
seizure/blackout 
% (n=12) 
Patients with 
likely first seizure  
 
% (n=40) 
GCS score 95% (55) 100% (12) 93% (37) 
Neurological exam 28% (16) 17% (2) 20% (8) 
Eyewitness account 88% (51) 75% (9) 83% (33) 
Review by senior ED 
doctor 
22% (13) 8% (1) 40% (16) 
Documented alcohol 
intake 
5% (3) 50% (6) 30% (12) 
Admission 71% (41) 67% (8) 88% (35) 
GCS, Glasgow coma scale; ED, Emergency department. 
 
 
3.2.3 UHA - Inpatient management 
ECG on admission was carried out in 95% (105/110), regardless of diagnosis. 11% 
(6/56) of patients with epilepsy taking AEDs had their drug levels checked98% 
(108/110) had their glucose levels checked. Only 19% (11/58) of patients with 
epilepsy had review or discussion with neurology during admission. 
 
Computed tomography (CT) was the primary imaging modality, only 6% (7/110) of 
patients had an MRI scan on admission. 83% (33/40) of patients with a likely first 
seizure had a CT head on admission. 50% (29/58) of patients with known epilepsy 
and 33% (4/12) of patients with previous seizure or blackout also underwent 
imaging.  
 
In those with known epilepsy who had a GCS of 13-15, 52% (15/29) had CT head 
imaging. 64% (21/33) of patients presenting with a likely first seizure with a GCS of 
13-15 had a CT. (Table 10, Figure 12) 
 
 
 
 
53 
 
Figure 12. CT head stratified by GCS score and diagnosis 
 
 
 
Table 10. Assessment and review during admission 
 Patients with 
diagnosis of 
epilepsy  
% (n=58) 
Patients with 
previous 
seizure/blackout  
% (n=12) 
Patient with likely 
first seizure  
% (n=40) 
CT 50% (29) 33% (4) 83% (33) 
CT - GCS 3-8 21% (6) 0% (0) 15% (5) 
CT- GCS 9-12 21% (6) 0% (0) 18% (6) 
CT - GCS 13-15 52% (15) 100% (4) 64% (21) 
CT – GCS unknown 7% (2) 0% (0) 3% (1) 
ECG 93% (54) 100% (12) 98% (39) 
Advice or review 
by neurology 
during admission 
19% (11) 8% (1) 15% (6) 
CT, computed tomography. ECG, electrocardiogram. 
 
In those presenting with a likely first seizure aged 60-69, 36% (12/33) had a CT as 
did 30% (10/33) of 70-79 year olds and 30% (10/33) of 80-89 year olds. (Table 11, 
Figure 13) 
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Figure 13. CT head stratified by age group and diagnosis 
 
 
 
Table 11. CT head by age group and diagnosis 
Age Patients with 
diagnosis of epilepsy  
% (n=29) 
Patients with 
previous 
seizure/blackout 
% (n=4) 
Patients with likely 
first seizure  
% (n=33) 
60-69 41% (12) 40% (2) 36% (12) 
70-79 41% (11) 20% (1) 30% (10) 
80-89 16% (5) 40% (2) 30% (10) 
>90 3% (1) 0 (0) 3% (1) 
CT, computed tomography. 
 
Review of CT head imaging in patients with epilepsy showed that 97% (28/29) who 
had undergone imaging had no new abnormalities or acute changes. The one 
abnormal scan showed a new subdural haematoma. Patient GCS on admission was 
9. 85% (28/33) of patients with a likely first seizure had a CT head scan which did 
not show any new abnormalities. 
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3.2.4 UHA - Care following admission 
Patients who died during admission were excluded from analysis of follow-up 
arrangements.  
1. Those recorded as having known epilepsy, prior to attendance, 6 deaths 
(n=52) 
2. Those known to have had previous seizures or blackouts, but not a diagnosis 
of epilepsy, 0 deaths (n=12) 
3. Those with likely first seizure, no previous seizures or blackouts or diagnosis 
of epilepsy, 3 deaths (n=37)  
 
There was no documentation with regards to management in the event of future 
seizures for all patients.  
 
In patients with known epilepsy 31% (16/52) were referred to neurology or epilepsy 
specialist on discharge. 50% (6/12) of those with previous blackouts and 27% 
(10/37) of patients with a likely first seizure were also referred.  
 
Amongst those with known epilepsy 10% (5/52) were referred to another medical 
speciality, these included a mixture of cardiology, department for medicine for 
older people and acute medical unit clinics.  14% (5/37) of those with a likely first 
seizure were referred to another speciality, these included cardiology and stroke 
specialities. 
 
In patients presenting with a likely first seizure 40% (4/10) aged 60-69 were 
referred to neurology or epilepsy specialist compared to 30% (3/10) of those aged 
80-89. (Table 12, Figure 14) 
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Figure 14. Referral to specialist services by age group 
 
 
 
Table 12. Referral to specialist services by age group 
 Patients with 
diagnosis of 
epilepsy 
% (n=52) 
Patients with 
previous 
seizures/blackout  
% (n=12) 
Patients with 
likely first seizure  
% (n=37) 
Epilepsy specialist 
referral as 
outpatient 
31% (16) 50% (6) 27% (10) 
Age 60-69 44% (7) 33% (2) 40% (4) 
Age 70-79 31% (5) 50% (3) 30% (3) 
Age 80-89 25% (4) 17% (1) 30% (3) 
Age >90 0% (0) 0% (0) 0% (0) 
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3.3 Results - Audit Royal Liverpool University Hospital  
 
98 patients were identified. A&E admission notes could not be found for 22 
patients. 16 patients’ case notes were off site and could not be retrieved. Analysis 
was carried out on the remaining 60 patients (median age 75, IQR 69-81, 50% 
male). 
For the purposes of analysis patients were divided into the following three 
categories: 
1. Those recorded as having known epilepsy, prior to attendance (28/60, 47%) 
2. Those known to have had previous seizures or blackouts, but not a diagnosis 
of epilepsy (4/60, 7%) 
3. Those with likely first seizures, no previous seizures or blackouts or 
diagnosis of epilepsy (28/60, 47%)  
 
 
3.3.1 RLH - Treatment prior to admission 
In those with known epilepsy 60% (17/28) had presented to ED with a seizure in the 
preceding 12 months, as had 50% (2/4) of patients with a previous seizure or 
blackout. Only 4% (1/28) of patients presenting with a likely first seizure had 
attended ED in the preceding 12 months. 
 
In patients with known epilepsy, 50% (14/28) had previously had a stroke, as had 
25% (7/28) of patients presenting with a likely first seizure. 36% (10/28) of patients 
with epilepsy had a pre-existing diagnosis of dementia, with only 14% (4/28) of 
patients presenting with a likely first seizure having the diagnosis. 
 
In those with a likely first seizure 36% (10/28) had two or more pre-existing 
comorbities. 43% (12/28) of patients with known epilepsy had two or more pre-
existing comorbities and 36% (10/28) had two pre-existing comorbidities. (Table 13, 
Figure 15) 
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Figure 15. Number of comorbidities by diagnosis 
 
 
 
Table 13. Number of comorbidities by diagnosis 
Number of 
comorbidities  
Patients with 
diagnosis of 
epilepsy   
% (n= 28) 
Patients with 
previous 
seizure/blackout  
% (n= 4) 
Patients with likely 
first seizure  
% (n= 28) 
0 4% (1) 25% (1) 11% (3) 
1 18% (5) 25% (1) 25% (7) 
2 36% (10) 0% (0) 29% (8) 
>2 43% (12) 50% (2) 36% (10) 
 
 
All patients with known epilepsy were on AED treatment (100%, 28/28). 64% 
(18/28) were on monotherapy, 36% (10/28) were on two or more AEDs or 
polytherapy. (Table 14, Figure 16) 
 
Sodium valproate was the most commonly used AED, 54% (15/28). 36% (10/28) of 
patients were on sodium valproate monotherapy, 14% (4/28) were on 
levetiracetam monotherapy, 11% (3/28) on phenytoin monotherapy and 7% (2/28) 
on lamotrigine monotherapy.   
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Within the known epilepsy group 21% (6/28) of patients had been reviewed by an 
epilepsy specialist or neurologist in the preceding year. None of the patients with 
known epilepsy had a care plan in place.  
 
Figure 16. Number of anti-epileptic drugs by diagnosis 
 
 
 
Table 14. Anti-epileptic drug treatment and review prior to presentation 
 Patients with 
diagnosis of 
epilepsy   
% (n= 28) 
Patients with 
previous 
seizure/blackout  
% (n= 4) 
Patients with likely 
first seizure  
% (n= 28) 
No AEDs 0% (0) 100% (4) 100% (2) 
Monotherapy 64% (18) 0% (0) 0% (0) 
Two or more 
AEDs 
36% (10) 0% (0) 0% (0) 
Specialist 
review previous 
12 months 
21% (6) 0% (0) 0% (0) 
AED, anti-epileptic drug. 
 
 
 
 
 
 
100% 100% 
64% 
36% 
0%
20%
40%
60%
80%
100%
120%
Patients with diagnosis of
epilepsy
Patients with previous
seizure/blackout
Patients with likely first seizure
Number of AEDs - 0 1 ≥2 
60 
 
3.3.2 RLH - Assessment on arrival 
GCS was checked in 93% (56/60) of all patients on arrival. All patients had their 
temperature, checked on arrival. 43% (12/28) of patients presenting with a likely 
first seizure and 25% (7/28) of those with known epilepsy had a neurological 
examination and plantars checked. None of the patients had examination of the 
fundi.  
 
An eyewitness account was sought in 86% (24/28) of patients presenting with a 
likely first seizure. 89% (25/28) of patients with known epilepsy presenting to ED 
also had an eyewitness account. 14% (4/28) of patients presenting with a likely first 
seizure had documentation regarding alcohol consumption.   
 
Senior review or discussion with a senior in ED within 4 hours of admission was 
carried out in 39% (11/28) of patients presenting with a likely first seizure and 43% 
(12/28) of patients with epilepsy. 
 
All patients with known epilepsy were admitted to hospital (100%, 28/28) as were 
93% (26/28) of those with a likely first seizure.  (Table 15, Figure 17) 
 
 
Figure 17. Admission to hospital and senior review in emergency department 
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Table 15. Assessments on arrival to emergency department 
 Patients with 
diagnosis of 
epilepsy  
% (n=28) 
Patients with 
known 
seizure/blackout  
% (n=4) 
Patients with 
likely first seizure 
% (n=28) 
GCS score 96% (27) 100% (4) 89% (25) 
Neurological exam 25% (7) 0% (0) 43% (12) 
Eyewitness account 89% (25) 75% (3) 86% (24) 
Review by senior ED 
doctor 
43% (12) 75% (3) 39% (11) 
Documented alcohol 
intake 
11% (3) 25% (1) 14% (4) 
Admission 100% (28) 100% (4) 93% (26) 
GCS, Glasgow coma scale; ED, Emergency department. 
 
 
3.3.3 RLH - Inpatient management 
All patients had their glucose checked. ECG was carried out in 90% (27/28) of 
patients with known epilepsy and 89% (25/28) of patients presenting with a likely 
first seizure.  
 
Computed tomography (CT) was the primary imaging modality carried out. 12% 
(7/60) of patients had an MRI scan on admission. 45% (13/28) of patients with a 
likely first seizure had a CT head on admission. 78% (21/28) of patients with known 
epilepsy, and 75% (3/4) of patients with previous seizure or blackout, also 
underwent CT imaging.  
 
CT imaging was carried out in 69% (9/13) of patients with epilepsy who had a GCS 
of 13-15. 67% (14/21) of patients presenting with a likely first seizure with a GCS of 
13-15 also had a CT scan.  (Table 16, Figure 18) 
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Figure 18. CT head stratified by GCS score and diagnosis 
 
 
 
Table 16. Assessment and review during admission 
 Patients with 
diagnosis of 
epilepsy  
% (n=28) 
Patients with 
previous 
seizure/blackout  
% (n=4) 
Patient with 
likely first seizure 
% (n=28) 
CT 45% (13) 75% (3) 78% (21) 
CT - GCS 3-8 15% (2) 67% (2) 5% (1) 
CT- GCS 9-12 8% (1) 0% (0) 19% (4) 
CT - GCS 13-15 69% (9) 33% (1) 67% (14) 
CT - GCS unknown 8% (1) 0% (0) 10% (2) 
ECG 96% (27) 100% (4) 89% (25) 
Advice or review by 
neurology/epilepsy 
during admission 
14% (4) 25% (1) 32% (9) 
CT, computed tomography. ECG, electrocardiogram. 
 
In patients presenting with a likely first seizure 19% (4/21) of those aged 60-69 had 
a CT scan as did 29% (6/21) of those aged 80-89. 23% (3/13) of 60-69 year olds with 
known epilepsy had CT imaging on admission compared to 31% (4/13) of those 
aged 80-89. (Table17, Figure 19) 
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Figure 19. CT head stratified by age group and diagnosis 
 
 
 
Table 17. CT head by age group and diagnosis 
Age Patient with 
diagnosis of epilepsy  
% (n=13) 
Patient with 
previous 
seizure/blackout  
% (n=3) 
Patients with likely 
first seizure 
% (n=21) 
60-69 23% (3) 0% (0) 19% (4) 
70-79 46% (6) 67% (2) 48% (10) 
80-89 31% (4) 33% (1) 29% (6) 
>90 0% (0) 0% (0) 5% (1) 
 
 
Review of CT head imaging carried out in patients with epilepsy did not show any 
new abnormalities or acute changes in 92% (12/13) of patients. The one abnormal 
scan in this group showed a possible small frontal subdural haematoma. The 
patient had a recorded GCS of 14. 
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3.3.4 RLH – Care following admission 
No patients died during their hospital admission. There was no documentation with 
regards to management in the event of future seizures for all patients.  
 
Referral to a neurology or epilepsy specialist on discharge was undertaken for 14% 
(4/28) of patients with known epilepsy. 50% (2/4) of those with previous blackouts 
and 43% (12/28) of patients with a likely first seizure.. 7% (2/28) of patients with 
epilepsy were referred to another medical speciality, stroke. 18%  (4/28) of those 
with a likely first seizure were also referred to another speciality, 
neurorehabilitation.  
 
The data was not stratified by age group due to the small sample size per group. 
(Table 16, Figure 18) 
 
Figure 20. Referral to epilepsy specialist services by diagnosis 
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3.4 Results - Comparison of National Audit Seizure Management in 
Hospital 2, University Hospital Aintree and Royal Liverpool University 
Hospital Audits 
 
In patients with known epilepsy, 66% (38/58) attending UHA and 64% (18/28) of 
those attending RLH were on monotherapy compared to only 59% (377/640) of 
patients in NASH2.  27% (175/640) of patients in NASH2 were on polytherapy 
compared to 31% (18/58) attending UHA and 36% (10/28) attending RLH. (Figure 
21) 
 
Figure 21. Number of anti-epileptic drugs in patients with epilepsy - Comparison 
between NASH2, UHA and RLH audits 
 
 
 
The rate of admission to hospital for patients with known epilepsy and previous 
blackout was highest for those attending RLH, with all patients who presented to ED 
being admitted to hospital. The rates of admission for patients with epilepsy were 
similar for UHA and NASH2. (Figure 22) 
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Figure 22. Admission to hospital - Comparison between NASH2, UHA and RLH 
audits 
 
 
 
In those with known epilepsy 50% (29/58) presenting with a seizure to ED at UHA 
had  CT head imaging as did 78% (21/27) for those attending RLH. The rates overall 
are much higher than those seen in NASH2 where 35% (226/640) of patients with 
known epilepsy, presenting with seizures had CT imaging. (Figure 23)  
 
 
Figure 23. CT head - Comparison between NASH2, UHA and RLH audits 
 
 
 
74% 
62% 
80% 
71% 
67% 
88% 
100% 100% 
93% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Patients with diagnosis of
epilepsy
Patients with previous
seizure/blackout
Patient with likely first seizure
NASH2 UHA RLH
35% 
44% 
71% 
50% 
33% 
83% 
45% 
75% 78% 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Patients with diagnosis of
epilepsy
Patients with previous
seizure/blackout
Patient with likely first seizure
NASH2 UHA RLH
67 
 
Advice or review by neurology during admission was requested in 32% (9/28) of 
patients presenting with a likely first seizure who attended RLH, compared to 15% 
(6/40) attending ED at UHA. In NASH2, 22% (143/640) of patients with epilepsy 
attending ED were discussed or reviewed by neurology compared to 14% (4/28) at 
RLH and 14% (8/58) attending UHA. (Figure 24) 
 
Figure 24. Advice or review by neurology during admission - Comparison between 
NASH2, UHA and RLH audits 
 
 
 
Referral to neurology or specialist on discharge was carried out in 11% (3/27) of 
patients attending RLH with known epilepsy. These figures were higher for both 
NASH2, 33% (206/622) of patients were referred, and UHA where 31% (16/52) of 
patients were referred.   
 
Referral to neurology or specialist on discharge for patients with a likely first seizure 
was carried out in 43% (12/28) of patients presenting to RLH, compared to 34% 
(131/390) in NASH2 and 27% (10/37) attending UHA. 50% of patients presenting 
with blackouts attending ED at UHA and RLH were referred to neurology or epilepsy 
specialist on discharge, compared to 42% (87/208) referred in NASH2. (Figure 25) 
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Figure 25. Referral to specialist services - Comparison between NASH2, UHA and 
RLH audits 
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Chapter 4.  Discussion 
 
4.1 Summary of Findings - National Audit for Seizure Management 
in Hospitals 2  
 
Given the varying presentations, the diagnosis of epilepsy can be more difficult in 
older people. Within NASH2 under thirty percent of patients with a previous 
diagnosis of epilepsy, had evidence of having seen an epilepsy specialist in the 
previous year. It seems that a large proportion of patients with active epilepsy are 
not being seen within epilepsy services, which leads to missed opportunities to 
optimise treatment and avoid further admissions to ED.  
 
Over half of patients with known epilepsy presenting with seizure to ED were on 
monotherapy. This again highlights the potential missed opportunity for improved 
seizure control. Breakthrough seizures in the elderly have consequences with 
regards to treatment, particularly in the context of polypharmacy, therefore input 
by specialist services is even more important. 
 
Sodium valproate was the most commonly prescribed AED, with over forty percent 
of patients with epilepsy, on polytherapy, on this AED. 
 
There was some variability with regards to investigations depending on diagnosis. 
ECGs were carried out in over ninety percent of patients presenting with a likely 
first seizure. However, this figure was lower for patients with a known diagnosis of 
epilepsy. It is important to recognize that older patients, even in the context of 
known epilepsy, can present with other pathologies leading to loss of consciousness 
and these should be explored. 
 
There was a statistically significant difference in admission rates in patients with 
epilepsy and likely first seizure, when comparing those aged 60 and over to those 
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under 60, with higher rates of admission in those aged 60 and over. It is difficult to 
explore this further given the retrospective nature of NASH2, social circumstances 
and pre-existing comorbid conditions may play a part. 
 
CT head imaging was undertaken in over seventy percent of patients presenting 
with a likely first seizure. Over thirty percent of patients with known epilepsy had 
CT head imaging. Patients’ with a GCS of less than 13 were more likely to have CT 
imaging.  The likelihood of CT head imaging did not vary considerably by age group. 
A significant number of patients with known epilepsy are having imaging following a 
seizure, this does not appear to correlate with age group.  
 
The difference in the numbers of CT head imaging carried out in patient aged 60 
and over and those under 60 is a statistically significant one, with higher rates of 
imaging seen in those aged 60 and over. Given the retrospective nature of NASH2 it 
is difficult to explore this further, however it is clear that a significant number of CT 
scans are carried out in patients with epilepsy presenting with a seizure. 
 
Compared to imaging, examination of patient’s fundi or plantar response was 
carried out in less than a third of patients, including those presenting with a first 
seizure. Although on the face of it imaging appears to have replaced basic 
neurological examination, this is likely to reflect lack of education and confidence in 
the management of these patients in ED. 
 
Eyewitness accounts were sought in eighty percent of patients presenting with a 
likely first seizure. In patients with a known diagnosis of epilepsy this was lower at 
seventy-three. Eyewitness accounts remain crucial in helping to ascertain a 
diagnosis of seizure or epilepsy, as highlighted in national guidelines. It is equally 
important to try and gain an eyewitness account for patients with known epilepsy, 
to re-affirm the initial diagnosis and ensure that a secondary diagnosis for the event 
is not missed. 
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Advice on management of further seizures was given to just over twenty percent of 
patients presenting with a likely first seizure. Those aged 60 to 69 with epilepsy 
were almost twice as likely to be given advice regarding further events compared to 
those aged 80 to 89. Conversely those aged 80 to 89 presenting with a likely first 
seizure were more likely to receive advice.  
 
Referral to neurology or epilepsy services on discharge was carried out in just over 
thirty percent of patients.  Double the number of 60 to 69 year olds presenting with 
a likely first seizure were referred compared to 80 to 89 year olds. Over half of 60-
69 year olds with known epilepsy, or previous seizure or blackout were referred on, 
compared to less than twenty per cent of 80 to 89 year olds.  
 
There was a statistically significant difference in rates of referral to specialist 
services for patients with first seizure and epilepsy when comparing those aged 60 
and over to the under 60, with higher rates of referral seen in those aged 60 and 
under. 
 
The reasons for non-referral to services are unclear, and may include inability to 
refer within hospitals, lack of services or a combination. This however does not 
account for the disparity in the rate of referrals between patients aged 60 and over 
and those under 60.  
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4.2 Summary of Findings - University Hospital Aintree Audit 
 
Over sixty percent of patients with epilepsy who attended ED had been seen by 
epilepsy specialists or neurologists in the preceding 12 months. This is higher than 
rates seen in NASH2, where just over thirty percent of patients with known epilepsy 
had been seen in specialist services. This may in part be due to the proximity of this 
hospital to a tertiary neurosciences’ unit.  
 
Although the figures from this analysis are higher than those from NASH2 there is 
still missed opportunity within this group of patients to optimise treatment.  
 
Over seventy percent of patients with a diagnosis of epilepsy attending ED were on 
monotherapy or on no treatment. Sodium valproate was the most commonly used 
anti-epileptic with over a third of patients with epilepsy on treatment with this AED. 
 
With regards to aetiology of seizures approximately forty percent of patients with 
known epilepsy had a previous diagnosis of stroke and around twenty percent had 
a pre-existing diagnosis of dementia. As well as epilepsy, over a third of these 
patients had two other comorbidities.  
 
Approximately thirty percent of patients presenting with their first seizure had an 
existing diagnosis of dementia.  Thirty eight percent of patients presenting with a 
likely first seizure had two or more pre-existing comorbidities. 
 
The importance of appropriate management and use of anti-epileptic medication is 
even more important in this group of patients particularly given the adverse effects 
of AEDs and their potential interactions with other medications. 
 
CT head imaging was carried out in more than eighty percent of patients with a 
likely first seizure. Conversely neurological examination was only carried out in a 
third of these patients.  
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More than fifty percent of patients with known epilepsy also had CT imaging, of 
these half had a GCS of 13-15. A higher percentage of patients with GCS of 13-15 
had CT imaging compared to those with a GCS of less than 13.  
 
Over ninety percent of patients with epilepsy who underwent CT imaging had scans 
which did not show any new abnormalities. This again highlights the high rate of CT 
imaging carried out in this group of patients, which for the majority does not lead to 
a change in management. 
 
Discussion with a senior in ED was carried out almost twice as often in patients 
presenting with a likely first seizure compared to those with known epilepsy. Advice 
from neurology services was sought in over ten percent of patients with known 
epilepsy who were admitted. This was similar for patients presenting with a first 
seizure.  
 
Over seventy percent of patients with known epilepsy were admitted to hospital as 
were almost ninety percent of patients presenting with a first seizure.  
 
There was no documented evidence about management of future seizures for any 
of these patients. It is possible that this was verbally passed on to patients, however 
if we assume that lack of documentation equates to this not being done, patients 
are being discharged home without advice in the event of future seizures.  
 
Approximately a third of patients with known epilepsy or likely first seizure are 
referred to neurology or specialist services on discharge. The rate of referral for 
patients with epilepsy decreases by increasing age bracket. With regards to onward 
referral to other specialities ten percent of patients with epilepsy and fourteen with 
a likely first seizure were referred to other medical specialities.  
 
Patients aged 60 and over with a likely first seizure are not referred to specialist 
services on discharge nor are they referred to other specialties for assessment. 
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There is therefore ongoing missed opportunities for these patients to have their 
management improved and hopefully avoid future ED attendance. 
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4.3 Summary of Findings - Royal Liverpool Hospital 
 
Twenty one percent of patients with epilepsy admitted to hospital had been seen 
by epilepsy specialists or neurologists in the preceding 12 months. This is lower 
than rates seen in NASH2, where just over thirty percent of patients with known 
epilepsy had been seen in specialist services.  
 
Sixty-four percent of patients with epilepsy were on monotherapy. Sodium 
valproate was used in over half of patients with epilepsy on polytherapy, these 
figures being higher than both UHA and NASH2.  
 
Fifty percent of patients with known epilepsy had a previous diagnosis of stroke and 
thirty-six percent had a pre-existing diagnosis of dementia. Over forty percent of 
patients with known epilepsy had more than two comorbid conditions in addition 
to epilepsy. These figures are higher than UHA, and it is difficult to explore this 
further. The difference may in part be related to the fact that these hospitals are in 
different geographic location within Liverpool and therefore may cater to different 
patient populations.  
 
Thirty six percent of patients presenting with a likely first seizure had more than 
two pre-existing comorbidities. A quarter of patients presenting with a likely first 
seizure had a pre-existing diagnosis of stroke and fourteen percent had a pre-
existing diagnosis of dementia.  
 
CT imaging was carried out in almost eighty percent of patients with a likely first 
seizure. Conversely neurological examination was only carried out in forty-three 
percent.   
 
Over sixty percent of patients with known epilepsy had CT imaging, and just over 
sixty percent of these had a GCS of 13-15. The number of CTs carried out appears to 
increase with GCS score, these findings are similar to those in UHA audit, but similar 
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trends were not seen in NASH2. It may be that these patients are too unstable to 
have CT imaging accounting for lower rates of CT imaging in patients with GCS of 
less than 13.  
 
Again over ninety percent of patients with epilepsy who underwent CT head 
imaging did not have any new abnormalities on scan. 
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4.4  Limitations 
 
As a retrospective audit, data collated in NASH2 could only be derived through 
information documented in the medical notes. As such some of the missing data 
may be due to variability of recording, or availability of the information at the time 
of data collection.  
 
A group of patients without a known diagnosis of epilepsy were on anti-epileptic 
medication. The nature of data collection in NASH2 did not allow retrospective 
review to ascertain whether this was in error or whether these drugs had been 
prescribed for different indications. 
 
Patients were divided into three groups in NASH2, and the same groups were 
retained for the purposes of analysis here. One of the groups contains patients 
where the diagnosis of epilepsy was not clear from the medical records. These 
patients were reported separately given that a retrospective diagnosis would not 
have been possible.  
 
Both UHA and RLH audits carry the same drawbacks. Given the retrospective nature 
of both audits, data could only be collected based on the information documented 
in the medical notes. UHA audit was carried out in a hospital which is in close 
proximity to a tertiary neurosciences unit and this may have some bearing on the 
results.   
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4.5 Implications  
 
Sodium valproate was the most commonly prescribed AED in NASH2 and local 
audits. This is likely to reflect the broad therapeutic spectrum and straightforward 
dosing schedule of this drug. (186-188) 
 
Focal epilepsy is more likely to be refractory to treatment and there is evidence 
that sodium valproate is not the best first AED to achieve seizure freedom. (87, 144, 
146, 171) A multi-centre double blind trial, comparing carbamazepine to sodium 
valproate, found that carbamazepine was more effective in the treatment of focal 
seizures, the two being equally effective for secondary generalised tonic–clonic 
seizures. Carbamazepine had fewer long term adverse effects than sodium 
valproate. (171) 
 
Sodium valproate has also been implicated in reduction of bone density in older 
people increasing the risk of fractures in this group. (129, 172, 173) The continued 
use of sodium valproate reflects outdated practice and is likely to be a consequence 
of management of these patients in primary care or by non-specialist services.  
 
To date only five randomised controlled trials of AED monotherapy in older people 
with newly diagnosed epilepsy have been carried out. (143, 145, 146, 159, 174) 
Four of the trials have shown comparable efficacy, in terms of time to first seizure, 
or seizure freedom between carbamazepine and lamotrigine. (143, 145, 146, 174) 
 
Retention rates were higher for lamotrigine than carbamazepine in these trials, 
mainly due to better tolerability with lamotrigine. The only prospective 
randomised, double-blind trial comparing levetiracetam, lamotrigine and 
carbamazepine controlled release in older patients with newly diagnosed epilepsy 
showed similar efficacy of levetiracetam monotherapy compared to carbamazepine 
controlled release. Tolerability was superior in levetiracetam leading to increased 
effectiveness in terms of retention rates. (159)  
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These findings do not seem to be reflected in clinical practice judging by the results 
of NASH2 and local audits where, by comparison, only a small percentage of 
patients were on lamotrigine, carbamazepine or levetiracetam monotherapy. 
 
A significant number of patients with known epilepsy are having imaging following a 
seizure. Whilst there appears to be some correlation between this and GCS score 
the same cannot be said when comparing patients aged 60 and over to those under 
60 in NASH2. This may be due to longer resolution of post-ictal confusion, Todd’s 
paresis or aphasia, thereby necessitating imaging in this group. (189)  
 
Review of CT head reports in patients with epilepsy was carried out for UHA and 
RLH. This showed that over ninety percent had imaging which did not show any 
new abnormalities or acute changes.  Previous studies have confirmed that CT 
imaging is carried out in over half of patients with epilepsy presenting to hospital 
with seizures. Prolonged altered consciousness, acute head trauma, and abnormal 
neurological examination at presentation were associated with an increased yield 
of ED neuroimaging. With the absence of any of these three clinical factors the true 
positive yield of neuroimaging was zero. (190) 
 
Lack of confidence in the management of these patients in conjunction with lack of 
input from specialist services may have led to CT imaging being used more 
frequently than perhaps it ought to be.  The need for imaging is likely to lead to 
longer admission times and perhaps unnecessary scans in this group of patients.   
 
Following NASH1 various aspects of care were highlighted as requiring 
improvement, patients presenting with seizures were managed in ED and referral 
rates to specialist services on discharge were low. (191)  
 
When comparing referral rates in patients aged under 60 to those aged 60 and 
over, for both epilepsy and first seizure, those aged 60 and over are far less likely to 
be referred to a specialist. This group is also not being referred to other medical 
specialities on discharge. This is in line with previous published data. (192)  
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Equitable access to specialist epilepsy services is important, particularly in older 
people where diagnosis can be more challenging. A study assessing this in Sheffield 
and Rotherham found that older patients with epilepsy were less likely to be 
referred to specialist neurology services than their younger counterparts, raising 
the possibility of age discrimination. (193) These findings are supported by the data 
collated in this study. 
 
The same group in Sheffield and Rotherham explored possible reasons for non-
referral, and identified a number of factors which may explain lower referral rates, 
including difficulty accessing hospital, patient reluctance to attend clinics, unclear 
referral pathway, complex differential diagnoses, referrer knowledge and time 
since onset. (194)  
 
When older patients were surveyed on the same questions many directly disagreed 
with these views. This data suggests that healthcare professionals may make 
assumptions about older people in terms of their willingness and ability to attend 
hospital appointments. (195) The sample size of professionals and patients was 
small and therefore further studies are needed to assess healthcare professionals’ 
attitudes.  
 
Older patients presenting with seizures are more likely to be admitted to hospital. 
Their other comorbidities and also safety concerns if they live alone, are factors 
which will influence admission and may make this more likely.  Advice on what to 
do in the event of further seizures is generally poor. It might be helpful for ED 
departments to have information leaflets available to give to patients on discharge.  
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Chapter 5. Recommendations 
 
The findings above show that there is inequality in access to specialist services in 
older people and this may in part reflect inadvertent age discrimination by 
clinicians. Given the rapidly increasing ageing population clinicians’ attitudes to the 
management of older patients must change in line with changing demographics. 
 
Whilst distance of travel may be related to difficulty accessing neurology or 
specialist clinics, these patients are not even considered for referral. This would 
imply that ED clinicians do not feel that this cohort of patients require review in 
either neurology or other medical speciality clinics. Clinician attitudes to 
management of this patient group has not been explored in the literature and 
further research is needed to establish why older patients with seizures and 
epilepsy are not managed more frequently in specialist care.  
 
The number of CT scans carried out in patients with epilepsy presenting to ED is far 
higher than one would expect. Conversely a neurological examination is carried out 
far less frequently. This is may highlight a degree of uncertainty by ED clinicians 
regarding the management of patients with epilepsy and seizures and further 
studies are required to explore this further. 
 
Lack of education, and perhaps lack of engagement with ED physicians, may be in 
part to blame for this trend. Teaching on management of seizures and epilepsy to 
EDs and acute medical units will give clinicians more confidence in assessment, 
investigation, management and choice of appropriate first line AED.  
 
Implementation of local referral pathways and guidelines, to help guide 
assessment, investigation, management and onward referral of patients with 
seizures and epilepsy is also likely to help increase clinician confidence.  
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It is equally important to highlight to referring trusts the services available from 
local neuroscience units for patients with seizures and epilepsy. This would increase 
assurance that these patients will be seen and assessed promptly, and thereby 
reducing the need for longer inpatient stays and investigation. 
 
Although improving management and increasing referral rates is important, 
considering their comorbidities and driving restrictions, older patients are likely to 
need access to local community clinics. This will require a review of the provision of 
services by healthcare providers to allow sufficient capacity in neurology and other 
specialist clinics for this patient cohort.  
 
Overall a combination of education, restructuring of services and further research 
will be required to improve standards of care for older patients with epilepsy and 
seizures. 
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Chapter 6. Conclusions 
 
There is considerable variation in the documented care of patients with seizures 
attending hospital and this is evident throughout the care pathway. Better 
management of these patients in the community would lead to lower admission 
rates in hospital.  
 
With a rapidly expanding ageing population, we have to be even more inclusive of 
the healthcare needs of this group of individuals, which can fundamentally improve 
their quality of life as well reducing unnecessary investigations and thereby longer 
hospital admissions.  
 
Although review of these patients within epilepsy services is ideal, this may not be 
feasible for every patient. Therefore, a stronger network between epilepsy 
specialists, primary care and elderly care physicians is needed to improve 
management and lower admission rates, thereby bringing about large cost savings. 
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Appendix 1. 
 
NASH2 Clinical Proforma Questions 
 
Q1.1 Auditor discipline 
Options: 
Doctor 
Nurse 
Other health professional 
 
Q2.2 Age 
 
Q2.3 Gender 
Options: 
Male 
Female 
 
Q2.4 Does the patient live in the geographical location covered by this trust? 
Options: 
Yes 
No/Not documented 
Q3.1 Is there a statement that the patient is known to have epilepsy? 
Options: 
Yes 
No/Not documented 
 
Q3.2 Does the patient have a written care plan in place? 
Options: 
Yes 
No/Not documented 
 
Q3.3 Is there documentation that the patient has had previous seizures or 
blackouts? 
Options: 
Yes 
No/Not documented 
 
Q3.3a Was the patient's previous seizure or blackout provoked by alcohol? 
Options: 
Yes 
No 
Not documented 
 
Q3.3b Was the patient's previous seizure or blackout provoked by head injury? 
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Options: 
Yes 
No 
Not documented 
 
Q3.3c Was the patient's previous seizure or blackout provoked by other? 
Options: 
Yes (if yes – please specify) 
No 
Not documented 
 
Q3.4 Has the patient attended this Emergency Department as a result of a sezirue 
in the previous 12 months? 
Yes 
No 
Not documented 
 
Q3.5 On attendance which anti-epileptic drugs was the patient being prescribed? 
Options: 
Carbamazepine/Tegretol/ Tegretol Retard 
Lamotrigine/Lamictal 
Levetiracetam/Keppra 
Phenytoin/Epanutin 
Sodium Valproate/Epilim/Epilim Chrono/Orlept 
Acetazolamide/Diamox 
Clobazam/Frisium 
Clonazepam/Rivotril/ Rivatril 
Diazepam/Valium 
Eslicarbazepine Acetate/ Zebinix 
Ethosuximide/Emeside/ Zarontin 
Gabapentin/Neurontin 
Lacosamide/Vimpat 
Oxcarbazepine/Trileptal 
Oxazepam/Serax 
Perampanel/Fycompa 
Pregabalin/Lyrica 
Phenobarbital 
Primidone/Mysoline 
Retigabine/Trobalt 
Rufinamide/Inovelon 
Stiripentol/Diacomit 
Sulthiame/Ospolot 
Tiagabine/Gabatril 
Topirimate/Topamax 
Vigabatrin/Sabril 
Zonisamide/Zonegran 
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Q3.6a Is it documented that the patient has seen an Epilepsy Specialist Nurse within 
the previous 12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6b Is it documented that the patient has seen a GPSI (neurology, epilepsy or 
neuropsychiatry) within the previous 12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6c Is it documented that the patient has seen a learning disability psychiatrist 
within the previous 12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6d Is it documented that the patient has seen a neurologist within the previous 
12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6e Is it documented that the patient has seen a paediatrician within the 
previous 12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6f Is it documented that the patient has seen a paediatric neurologist within the 
previous 12 months? 
Options: 
Yes 
No 
Not documented 
 
Q3.6g Is it documented that the patient has seen a neurosurgeon within the 
previous 12 months? 
Options: 
Yes 
No 
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Not documented 
 
Q3.7 Is the patient recorded as having a learning disability? 
Options: 
Yes 
No/Not documented 
 
Q4.1 When did the patient arrive in the Emergency Department? 
Date 
 
Q4.2 Is there evidence of senior Emergency Department review, i.e. was the patient 
seen (or was there a consultation regarding the patient)? 
Options: 
Yes 
No 
Not documented 
 
Q4.2a Was this within 4 hours of arrival in the Emergency Department? 
Options: 
Yes 
No 
Not documented 
 
Q4.2b Were they seen by a consultant? 
Options: 
Yes 
No 
Not documented 
 
Q4.2a Were they seen by a ST4 or above? 
Options: 
Yes 
No 
Not documented 
 
Q5.1a Is it documented that diazepam (rectal or IV) was administered prior to 
arrival at hospital? 
Options: 
Yes 
No 
 
Q5.1a1 Who was the diazepam administered by? 
Options: 
Family member/carer 
GP 
Ambulance staff 
Other - please specify 
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Q5.1b Is it documented that midazolam was administered prior to arrival at 
hospital? 
Options: 
Yes 
No 
 
Q5.1b1 Who was the midazolam administered by? 
Options: 
Family member/carer 
GP 
Ambulance staff 
Other - please specify 
 
Q5.1c Is it documented that an other drug (oral clobazam, iv lorazepam or 
paraldehyde) was administered prior to arrival at hospital? 
Options: 
Yes 
No 
 
Q5.1c1 Who was the other drug administered by? 
Options: 
Family member/carer 
GP 
Ambulance staff 
Other - please specify 
 
Q5.2 Had the seizure stopped by the time of arrival in the emergency room? 
Options: 
Yes 
No 
Unclear 
 
Q5.2a What treatment was given in the emergency room? 
Options: 
IV diazepam 
Rectal diazepam 
Buccal midazolam 
IV glucose 
IV levetiracetam 
IV lorazapam 
IV phenobarbitol 
IV phenytoin 
IV thiamine / pabrinex 
IV valproate 
Rectal or intramuscular paraldehyde 
 
Q6.1 Was the patient fully conscious upon arrival at the Emergency Department? 
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Options: 
Yes 
No 
Don’t know 
 
Q6.2a Was the patient’s temperature taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2a1 What was the patients’ temperature? 
Options: 
Numeric figure 
 
Q6.2a2 Was their temperature taken within 20 minutes of arrival? 
Options: 
Yes 
No/Don’t know 
 
Q6.2b Was the patient’s pulse taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2c Was the patient’s blood pressure taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2d Was the patient’s oxygen saturation taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2e Was the patient’s respiratory rate taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2f Was the patient’s GCS taken in the Emergency Department? 
Options: 
Taken 
Not taken/Don’t know 
 
Q6.2f1 What was their GCS score? 
Options: 
1-15 
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Q6.3 In the 4 hours following the patient’s arrival at the Emergency Department 
was a neuro obs chart in place? 
Options: 
Yes 
No/Don’t know 
 
Q6.4 Where was the patient transferred or admitted to, directly from the 
Emergency Department? 
Options: 
Clinical decision unit 
ED observational ward 
EMU or equivalent 
Intensive Care Unit 
Medical decision unit 
Medical ward 
Neurology ward 
Other - please specify 
Discharged 
 
Q6.4a For all patients except those who were discharged (or for whom the answer 
to the previous question was missing), who took over the care of the patient during 
admission? 
Options: 
Neurologist 
General physician 
Other 
Remained under care of Emergency Department 
 
Q6.4b For all patients except those who were discharged (or for whom the answer 
to the previous question was missing), how long was the patient admitted for? 
Options: 
Days 
Hours 
 
Q6.4c For patients who were moved to the Intensive Care Unit, what were they 
treated with? 
Options: 
Heminevrin Yes; No; Don’t know 
Midazolam Yes; No; Don’t know 
Phenobarbitol/phenobarbitone Yes; No; Don’t know 
Propofol Yes; No; Don’t know 
Thiopentone Yes; No; Don’t know 
Other - please specify Yes; No; Don’t know 
 
Q6.5 Was an eyewitness to the seizure contacted? 
Options: 
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Yes 
No 
Don’t know 
Event unwitnessed 
 
Q6.5a If no to the above, is there a statement that an attempt was made to 
conatact an eyewitness? 
Options: 
Yes 
No 
 
Q6.6 Is there documentation that the patient was asked as to whether or not they 
are a driver? 
Options: 
Yes 
No 
Not applicable 
 
Q6.7 Is there documentation of the patient’s general alcohol intake? 
Options: 
Yes 
No 
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Q6.7a How is their drink intake best classified? 
Options: 
Excessive 
Moderate 
Low 
 
Q6.8 In the week prior to arrival at the Emergency Department is it documented 
that the patient has been on an alcoholic binge? 
Options: 
Yes 
No 
 
Q6.9 Is there documentation that the patient does or does not use illicit drugs? 
Options: 
Yes 
No 
 
Q6.9a Are they a user or a non-user? 
Options: 
User 
Non-user 
 
Q6.9b Which drugs do they use? 
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Options: 
Cannabis 
Opiates 
Stimulants 
Other - please specify 
 
Q6.10 In the 24 hours prior to arrival at the Emergency Department is it 
documented that the patients has been using illicit drugs? 
Options: 
Yes 
No 
 
Q6.11a Is there documentation of a fundi examination being undertaken at any 
time during attendance at the Emergency Department? 
Options: 
Yes 
No 
 
Q6.11b Is there documentation of a plantar examination being undertaken at any 
time during attendance at the Emergency Department? 
Options: 
Yes 
No 
 
Q7.1 Is it documented that at any point in time advice was sought from a neurology 
/ epilepsy team, or an assessment taken by a neurologist or epilepsy specialist? 
Options: 
Yes 
No 
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Q7.1a From whom was advice sought? 
Options: 
Epilepsy Specialist Nurse 
Neurologist 
Neuropsychiatrist 
Neurosurgeon 
Paediatrician 
Paediatric neurologist 
 
Q8.1a Were antiepileptic drug level investigations undertaken following attendance 
in the Emergency Department? 
Options: 
Yes 
No 
Don’t know 
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Q8.1b Were CT (head) investigations undertaken following attendance in the 
Emergency Department? 
Options: 
Yes 
No 
Don’t know 
 
Q8.1c Were ECG investigations undertaken following attendance in the Emergency 
Department? 
Options: 
Yes 
No 
Don’t know 
 
Q8.1d Were EEG investigations undertaken following attendance in the Emergency 
Department? 
Options: 
Yes 
No 
Don’t know 
 
Q8.1e Were glucose levels/BM investigations undertaken following attendance in 
the Emergency Department? 
Options: 
Yes 
No 
Don’t know 
 
Q8.1f Were MRI (head) investigations undertaken following attendance in the 
Emergency Department? 
Options: 
Yes 
No 
Don’t know 
 
 
Q8.2 Did the patient die during their admission? 
Options: 
Yes 
No 
 
Q8.2a What was the cause of death? 
Options: 
Free text entries 
 
Q8.3a Was a CT (head) investigation requested as an outpatient following 
discharge? 
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Options: 
Yes 
No 
Don’t know 
 
 
Q8.3b Was a EEG investigation requested as an outpatient following discharge? 
Options: 
Yes 
No 
Don’t know 
 
Q8.3c Was a MRI (head) investigation requested as an outpatient following 
discharge? 
Options: 
Yes 
No 
Don’t know 
 
Q8.3d Was a 12 lead ECG investigation requested as an outpatient following 
discharge? 
Options: 
Yes 
No 
Don’t know 
 
Q9.1 What was the diagnosis at discharge/death? 
Options: 
Blackout with seizure markers, not sure if seizure 
Syncope/faint 
First unprovoked seizure 
Unprovoked seizures with history of previous seizures, but no current epilepsy 
diagnosis 
Seizure in someone with established diagnosis of epilepsy 
Provoked seizure – alcohol induced 
Provoked seizure – drug induced 
Provoked seizure – head injury 
Provoked seizure – acute stroke 
Psychogenic non-epileptic attack / pseudoseizure 
Self-discharged 
Other - please specify 
Not recorded 
 
Q9.2 Was the patient sent home on any antiepileptic drugs? 
Options: 
Yes 
No/Don’t know 
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Q9.2a Which drugs were they sent home on? 
Options: 
Carbamazepine/Tegretol/ Tegretol Retard 
Lamotrigine/Lamictal 
Levetiracetam/Keppra 
Phenytoin/Epanutin 
Sodium Valproate/Epilim/Epilim Chrono/Orlept 
Acetazolamide/Diamox 
Clobazam/Frisium 
Clonazepam/Rivotril/ Rivatril 
Diazepam/Valium 
Eslicarbazepine Acetate/ Zebinix 
Ethosuximide/Emeside/ Zarontin 
Gabapentin/Neurontin 
Lacosamide/Vimpat 
Oxcarbazepine/Trileptal 
Oxazepam/Serax 
Perampanel/Fycompa 
Pregabalin/Lyrica 
Phenobarbital 
Primidone/Mysoline 
Retigabine/Trobalt 
Rufinamide/Inovelon 
Stiripentol/Diacomit 
Sulthiame/Ospolot 
Tiagabine/Gabatril 
Topirimate/Topamax 
Vigabatrin/Sabril 
Zonisamide/Zonegran 
 
Q9.3 Was advice about driving to the patient given? 
Options: 
Yes 
No 
Don’t know 
Not applicable (patient does not drive) 
 
Q9.3a Was it that they should stop driving? 
Options: 
Yes 
No 
Don’t know 
 
Q9.3b Was it that they should inform DVLA? 
Options: 
Yes 
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No 
Don’t know 
 
Q9.4 Was the management of future seizures discussed with the patients or carers? 
Options: 
Yes 
No 
Not documented 
 
10.1a Was the patient referred to an epilepsy service or first fit clinic? 
Options: 
Yes 
No 
Don’t know 
 
10.1b Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1c What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1d What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
10.1e Was the patient referred to an epilepsy specialist nurse? 
Options: 
Yes 
No 
Don’t know 
 
10.1f Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
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10.1g What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1h What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
10.1i Was the patient referred to a GPSI epilepsy? 
Options: 
Yes 
No 
Don’t know 
 
10.1j Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1k What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1l What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
10.1m Was the patient referred to a learning disability psychiatrist? 
Options: 
Yes 
No 
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Don’t know 
10.1n Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1o What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1p What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
10.1q Was the patient referred to a neurologist at this Trust / Health Board? 
Options: 
Yes 
No 
Don’t know 
 
10.1r Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1s What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1t What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
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Other - please specify 
 
10.1u Was the patient referred to a neurologist at another Trust / Health Board? 
Options: 
Yes 
No 
Don’t know 
 
10.1v Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1w What was the date of their appointment? 
Options: 
Free text 
Date not known 
10.1x What was their diagnosis? 
Options: 
Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
10.1y Was the patient referred to an alcohol/drug liaison service? 
Options: 
Yes 
No 
Don’t know 
 
10.1z Did the patient attend their appointment? 
Options: 
Yes 
No 
Don’t know 
 
10.1aa What was the date of their appointment? 
Options: 
Free text 
Date not known 
 
10.1bb What was their diagnosis? 
Options: 
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Blackout of uncertain cause 
Blackout with other cardiac cause 
Epilepsy 
First epileptic seizure 
Non epileptic attack disorder (NEAD) 
Syncope/fait/low blood pressure 
Other - please specify 
 
Q10.2 Was an A&E discharge letter provided to the patient’s GP following their 
attendance at ED? 
Options: 
Yes 
No 
Don’t know 
 
Q10.2a Did the letter ask their GP to arrange onward referral? 
Options: 
Yes 
No 
Don’t know 
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Appendix 2.  
 
Audit Collection Proforma: UHA and RLH Audit 
Demographics 
Patient audit number  
Age  
Gender 
(Male/Female) 
 
 
Clinical information 
Is the patient known to have epilepsy? (Please circle) 
Yes                                                       No 
Is there a written care plan in place? (Please circle) 
 
Yes                                                       No 
Documentation of previous seizures/blackouts? (Please circle) 
Yes                                                        No 
If Yes date of last 
seizure/seizures………………………………………………………………………………………………………
…………………………………… 
Was the seizure provoked by: (Please circle) 
alcohol  
head injury 
other 
(specify)……………………………………………………………………………………………..……………………
…………………………………………………… 
Has there been admission in the last 12 months to the department due to 
seizure? (Please circle) 
Yes                             No                              Unknown 
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Any other known comorbidities? (Please list) 
………………………………………………………………………………………………………………………..………
……………………………………………………………… 
Does the patient drink alcohol? (Please circle) 
Yes                             No                              Unknown 
If Yes how many units a 
week…………………………………………………………………………..……………………………………………
………………………. 
Does the patient use illicit drugs? (Please circle) 
Yes                             No                              Unknown 
If Yes specify time drugs last 
used……………..…………………………………………………………………………..………………………………
……………… 
Antiepileptic medication on admission (Please list) 
………………………………………………………………………………………………………………………..………
…………………………………………………………… 
Other medication on admission (Please list) 
………………………………………………………………………………………………………………………...………
…………………………………………………………… 
Does the patient drive? (Please circle) 
Yes                             No                              Unknown                            
Is the patient under the care of Walton Centre for management of their epilepsy? 
(Please circle) 
Yes                             No                              Unknown 
If yes date of last appointment/name of person seen………………………………………… 
 
Admission 
Date and time of admission to A&E 
……………………………………………………………………………………………………………………… 
Was there A&E senior review within 4 hours (SpR/Consultant)? (Please circle) 
Yes                             No                              Unknown 
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Were any of the following medication given prior to admission and if so by 
whom? 
Diazepam                 Yes                          No 
(Paramedic/GP/Family/Other - 
specify)………………………………………………………………………………………………… 
Midazolam               Yes                          No 
(Paramedic/GP/Family/Other - 
specify)…………………………………………………………………………………… 
Other (Lorazepam/Clobazam/Paraldehyde)                 Yes                          No 
(Paramedic/GP/Family)…………………………………………………………………………………… 
Had seizure stopped on arrival to A&E? (Please circle) 
Yes                             No                              Unknown 
Was an eyewitness account sought? (Please circle) 
Yes                             No                              Unknown 
 
Observations/Examination 
What was the patient’s GCS on arrival? 
Eyes……………….Verbal…………….Motor…………….. Total ………………………../15 
 
Was a neuro observation chart started within 4 hours of admission? (Please circle) 
Yes                             No                              Unknown 
Which of the following were checked? (Please circle) 
Temperature            Yes                             No                              Unknown 
Blood pressure        Yes                             No                              Unknown 
Heart rate                 Yes                             No                              Unknown 
O2 saturation          Yes                             No                              Unknown 
Respiratory rate      Yes                             No                              Unknown 
Was a neurological examination carried out? (Please circle) 
Yes                             No                              Unknown 
If yes is there documentation of the following? (Please circle) 
Plantar response      Yes                             No                              Unknown 
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Fundoscopy                Yes                             No                              Unknown 
Investigations 
Were any of the following investigations carried out as an inpatient? (Please 
circle) 
Anti-epileptic blood levels       Yes                            No                                Unknown 
Glucose levels                             Yes                           No                                Unknown 
Electrolytes (Na/Ca)                  Yes                            No                                Unknown 
CT head                                        Yes                            No                               Unknown 
MRI head                                      Yes                           No                                Unknown 
EEG                                                Yes                           No                                Unknown 
ECG                                                Yes                           No                                Unknown 
Were any of the following investigations arranged on an outpatient basis? (Please 
circle) 
CT head                                       Yes                             No                              Unknown 
If yes date arranged……………………………………….. 
MRI head                                     Yes                             No                              Unknown 
If yes date arranged……………………………………….. 
EEG                                                Yes                             No                              Unknown 
If yes date arranged……………………………………….. 
ECG                                                Yes                             No                              Unknown 
If yes date arranged……………………………………….. 
 
Inpatient stay 
Where was the patient transferred/admitted to from A&E? (Please circle) 
 
Clinical decision unit (or equivalent) 
Medical assessment unit (or equivalent) 
Medical ward 
Neurology 
Intensive care unit 
Discharged 
 
What was the duration of admission (hours/days)? 
Total number: ……………hours ……………………days 
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Did the patient die during admission? (Please circle) 
Yes                             No 
 
Diagnosis/Discharge 
What was the diagnosis on discharge? (Please circle) 
Seizure (Patient with known 
epilepsy) 
First unprovoked seizure 
Blackout with seizure markers 
(not clear if seizure) 
Syncope/faint 
Non-epileptic attack 
 
Self discharged 
 
Provoked seizure – acute stroke  
Provoked seizure – alcohol induced 
Provoked seizure – head injury 
Provoked seizure – drug induced 
Provoked seizure – other 
(sepsis/metabolic/tumour etc/please 
specify)…………………………………………………………………
………………. 
 
 
Was advice about driving given? (Please circle) 
Yes                             No                              Unknown 
Was the patient discharged home on anti-epileptic medication? (Please circle) 
Yes                             No                              Unknown 
If Yes please list 
medication………………………………………………………………………………………………………………
…………………………………… 
Was the patient referred to a neurologist for follow-up? (Please circle) 
Yes                             No                              Unknown 
 
Was the patient referred to any other hospital speciality for follow-up? (Please 
circle) 
Yes                             No                              Unknown 
If Yes please list 
specialist……………………………………………………………………………………………………………………
…………………………………….. 
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